CN115969853A - Novel heterocyclic derivatives useful as SHP2 inhibitors - Google Patents
Novel heterocyclic derivatives useful as SHP2 inhibitors Download PDFInfo
- Publication number
- CN115969853A CN115969853A CN202211420369.9A CN202211420369A CN115969853A CN 115969853 A CN115969853 A CN 115969853A CN 202211420369 A CN202211420369 A CN 202211420369A CN 115969853 A CN115969853 A CN 115969853A
- Authority
- CN
- China
- Prior art keywords
- tert
- piperidine
- dihydrospiro
- stirred
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims abstract description 11
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 title abstract description 84
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 171
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 3
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 3
- 206010029748 Noonan syndrome Diseases 0.000 claims description 3
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- GKGIGIUNYOFYHZ-LJQANCHMSA-N (5S)-1'-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[5,7-dihydrocyclopenta[b]pyridine-6,4'-piperidine]-5-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2(CC1)[C@@H](C=1C(=NC=CC=1)C2)N GKGIGIUNYOFYHZ-LJQANCHMSA-N 0.000 claims 1
- GKGIGIUNYOFYHZ-UHFFFAOYSA-N NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2(CC1)C(C=1C(=NC=CC=1)C2)N Chemical compound NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2(CC1)C(C=1C(=NC=CC=1)C2)N GKGIGIUNYOFYHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000013521 Visual disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 2
- -1 heterocyclic pyrazine compounds Chemical class 0.000 description 147
- 239000000243 solution Substances 0.000 description 131
- 239000000203 mixture Substances 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 103
- 239000012074 organic phase Substances 0.000 description 103
- 239000011734 sodium Substances 0.000 description 96
- 238000006243 chemical reaction Methods 0.000 description 94
- 125000000217 alkyl group Chemical group 0.000 description 91
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 81
- 239000012267 brine Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 57
- 125000001309 chloro group Chemical group Cl* 0.000 description 48
- 238000001914 filtration Methods 0.000 description 48
- 238000000034 method Methods 0.000 description 48
- 238000010898 silica gel chromatography Methods 0.000 description 48
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 47
- 239000000543 intermediate Substances 0.000 description 46
- 238000001816 cooling Methods 0.000 description 43
- 125000001072 heteroaryl group Chemical group 0.000 description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 40
- 125000003545 alkoxy group Chemical group 0.000 description 38
- 238000001035 drying Methods 0.000 description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 36
- 125000001424 substituent group Chemical group 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229910052736 halogen Inorganic materials 0.000 description 28
- 150000002367 halogens Chemical class 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 238000003756 stirring Methods 0.000 description 28
- 125000005842 heteroatom Chemical group 0.000 description 27
- 229910052799 carbon Inorganic materials 0.000 description 25
- 125000004043 oxo group Chemical group O=* 0.000 description 25
- 125000004452 carbocyclyl group Chemical group 0.000 description 24
- 239000007858 starting material Substances 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 20
- 239000008346 aqueous phase Substances 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 239000012299 nitrogen atmosphere Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 150000001721 carbon Chemical group 0.000 description 14
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 13
- 239000003039 volatile agent Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- XMLJLHMBVQJFFR-UHFFFAOYSA-N 3-(2-amino-3-chloropyridin-4-yl)sulfanyl-6-chloropyrazin-2-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1C(=NC(=CN1)Cl)N XMLJLHMBVQJFFR-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- RRAMTOSLXCIPSZ-UHFFFAOYSA-N tert-butyl 5-bromo-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC3=CC=C(Br)C=C3C2=O)CC1 RRAMTOSLXCIPSZ-UHFFFAOYSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- MYHJCTUTPIKNAT-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 MYHJCTUTPIKNAT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 5
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 102200155477 rs397507511 Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- FQZLNQAUUMSUHT-UHFFFAOYSA-N tert-butyl n,n-bis(2-chloroethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCl)CCCl FQZLNQAUUMSUHT-UHFFFAOYSA-N 0.000 description 4
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 3
- WRMYXTBEGJGXMY-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]-4-(thiophen-2-ylmethyl)piperidine-4-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C(=O)O)CC=1SC=CC=1 WRMYXTBEGJGXMY-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- NNEAKBWZBQOQDH-UHFFFAOYSA-N 3-(1h-inden-2-yl)pyridine Chemical compound C=1C2=CC=CC=C2CC=1C1=CC=CN=C1 NNEAKBWZBQOQDH-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 102000014400 SH2 domains Human genes 0.000 description 3
- 108050003452 SH2 domains Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- GSEZHCLWHDZJAB-UHFFFAOYSA-N oxan-4-yl methanesulfonate Chemical compound CS(=O)(=O)OC1CCOCC1 GSEZHCLWHDZJAB-UHFFFAOYSA-N 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102200155730 rs121918454 Human genes 0.000 description 3
- 102200155722 rs121918465 Human genes 0.000 description 3
- 102200155470 rs397507510 Human genes 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 3
- ZLIMLJIEEQNKJK-LJQANCHMSA-N (1S)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-6-methoxyspiro[1,3-dihydroindene-2,4'-piperidine]-1-amine Chemical compound COc1ccc2CC3(CCN(CC3)c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)[C@H](N)c2c1 ZLIMLJIEEQNKJK-LJQANCHMSA-N 0.000 description 2
- OSKLARGYVMOWIX-GOSISDBHSA-N (1S)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1-amine Chemical compound N[C@@H]1C2=CC=CC=C2CC11CCN(CC1)C1=CN=C(SC2=C(Cl)C(N)=NC=C2)C(N)=N1 OSKLARGYVMOWIX-GOSISDBHSA-N 0.000 description 2
- JQWNFSPWFPFYOX-JOCHJYFZSA-N (1S)-1'-[6-amino-5-[(3-fluoro-1H-indol-4-yl)sulfanyl]pyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1-amine Chemical compound N1C2=C(C(=C1)F)C(SC1=NC=C(N3CCC4(CC3)CC3=CC=CC=C3[C@H]4N)N=C1N)=CC=C2 JQWNFSPWFPFYOX-JOCHJYFZSA-N 0.000 description 2
- PYGGEOFNOAVTCT-UHFFFAOYSA-N (2-chloro-1,3-thiazol-4-yl)methanol Chemical compound OCC1=CSC(Cl)=N1 PYGGEOFNOAVTCT-UHFFFAOYSA-N 0.000 description 2
- PRMLMDSFLIHHSO-UHFFFAOYSA-N (2-methylpyridin-3-yl)methanol Chemical compound CC1=NC=CC=C1CO PRMLMDSFLIHHSO-UHFFFAOYSA-N 0.000 description 2
- LIUGYEURYFTFFQ-MRXNPFEDSA-N (2R)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,2-dihydroindene-3,4'-piperidine]-2-amine Chemical compound N[C@@H]1CC2=CC=CC=C2C11CCN(CC1)C1=CN=C(SC2=C(Cl)C(N)=NC=C2)C(N)=N1 LIUGYEURYFTFFQ-MRXNPFEDSA-N 0.000 description 2
- HOVCGEVZLGMGSK-UHFFFAOYSA-N (3-bromo-6-chloropyridin-2-yl)methanol Chemical compound OCC1=NC(Cl)=CC=C1Br HOVCGEVZLGMGSK-UHFFFAOYSA-N 0.000 description 2
- XKJANTSBZUMIDC-GOSISDBHSA-N (3S)-3-amino-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-5-ol Chemical compound C1(=C(Cl)C(SC2=NC=C(N3CCC4(CC3)CC3=CC=C(O)C=C3[C@H]4N)N=C2N)=CC=N1)N XKJANTSBZUMIDC-GOSISDBHSA-N 0.000 description 2
- YMFDHAOBUOVUNL-UHFFFAOYSA-N (4-phenylmethoxypyridin-2-yl)methanol Chemical compound C1=NC(CO)=CC(OCC=2C=CC=CC=2)=C1 YMFDHAOBUOVUNL-UHFFFAOYSA-N 0.000 description 2
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 2
- BJTPHZIHVVDBFE-UHFFFAOYSA-N 1'-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxospiro[1H-indene-2,4'-piperidine]-5-carboxylic acid Chemical compound C1(=O)C2=C(C=CC(C(=O)O)=C2)CC21CCN(CC2)C(=O)OC(C)(C)C BJTPHZIHVVDBFE-UHFFFAOYSA-N 0.000 description 2
- SFFIZVLMPQXTOG-UHFFFAOYSA-N 1'-benzyl-6-hydroxyspiro[3H-indene-2,4'-piperidine]-1-one Chemical compound C(C1=CC=CC=C1)N1CCC2(CC1)C(C1=CC(=CC=C1C2)O)=O SFFIZVLMPQXTOG-UHFFFAOYSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- MJAOYLLMJPMONH-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-(2-bromobenzoyl)piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)C1=C(Br)C=CC=C1 MJAOYLLMJPMONH-UHFFFAOYSA-N 0.000 description 2
- BGFAARWZDFYNPO-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-(3-methylpyridin-2-yl)piperidine-1,4-dicarboxylate Chemical compound CC=1C(=NC=CC=1)C1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)OCC BGFAARWZDFYNPO-UHFFFAOYSA-N 0.000 description 2
- YFKMSDFBFPIIBY-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[(2-bromophenyl)-hydroxymethyl]piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)C(O)C1=C(Br)C=CC=C1 YFKMSDFBFPIIBY-UHFFFAOYSA-N 0.000 description 2
- PAHVDQLILBAUOO-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[(2-chloro-1,3-thiazol-4-yl)methyl]piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)CC=1N=C(SC=1)Cl PAHVDQLILBAUOO-UHFFFAOYSA-N 0.000 description 2
- FMXNFYIJQBKBDD-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[(2-chloro-1,3-thiazol-5-yl)methyl]piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(Cc2cnc(Cl)s2)CCN(CC1)C(=O)OC(C)(C)C FMXNFYIJQBKBDD-UHFFFAOYSA-N 0.000 description 2
- GITVELLRQZUIHW-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[(2-methylpyridin-3-yl)methyl]piperidine-1,4-dicarboxylate Chemical compound C(OC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=CN=C1C)C GITVELLRQZUIHW-UHFFFAOYSA-N 0.000 description 2
- LGGZSCXGXMAIDZ-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[(3-bromo-6-chloropyridin-2-yl)methyl]piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CC2=NC(Cl)=CC=C2Br)CCN(CC1)C(=O)OC(C)(C)C LGGZSCXGXMAIDZ-UHFFFAOYSA-N 0.000 description 2
- HYBBMZLQFMUJMN-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-[hydroxy-(4-phenylmethoxypyridin-2-yl)methyl]piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)C(O)c1cc(OCc2ccccc2)ccn1 HYBBMZLQFMUJMN-UHFFFAOYSA-N 0.000 description 2
- VOUOYVKFHWUHNG-UHFFFAOYSA-N 1-amino-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,3-dihydroindolizine-2,4'-piperidine]-7-one Chemical compound C1(=C(SC2=NC=C(N3CCC4(C(C=5N(C4)C=CC(=O)C=5)N)CC3)N=C2N)C=CN=C1N)Cl VOUOYVKFHWUHNG-UHFFFAOYSA-N 0.000 description 2
- ZQZVWDXMUCTNRI-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-methylpiperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(C)CCN(C(=O)OC(C)(C)C)CC1 ZQZVWDXMUCTNRI-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- ZELUAAXEWIYSLH-UHFFFAOYSA-N 2-(2-bromopyridin-3-yl)acetonitrile Chemical compound BrC1=NC=CC=C1CC#N ZELUAAXEWIYSLH-UHFFFAOYSA-N 0.000 description 2
- MIZIOHLLYXVEHJ-UHFFFAOYSA-N 2-[benzyl(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CC1=CC=CC=C1 MIZIOHLLYXVEHJ-UHFFFAOYSA-N 0.000 description 2
- 125000004011 3 membered carbocyclic group Chemical group 0.000 description 2
- OEYHXVWCRYKDPX-UHFFFAOYSA-N 3-(2-amino-3-chloropyridin-4-yl)sulfanyl-6-(3-iminospiro[1H-indene-2,4'-piperidine]-1'-yl)pyrazin-2-amine Chemical compound C1(=C(SC2=NC=C(N3CCC4(C(=N)C5=C(C4)C=CC=C5)CC3)N=C2N)C=CN=C1N)Cl OEYHXVWCRYKDPX-UHFFFAOYSA-N 0.000 description 2
- CCEUJKKUJAYIAM-UHFFFAOYSA-N 3-(bromomethyl)-2-methylpyridine Chemical compound CC1=NC=CC=C1CBr CCEUJKKUJAYIAM-UHFFFAOYSA-N 0.000 description 2
- GTTQRVGVEIXEHQ-UHFFFAOYSA-N 3-chloro-4-iodopyridin-2-amine Chemical compound NC1=NC=CC(I)=C1Cl GTTQRVGVEIXEHQ-UHFFFAOYSA-N 0.000 description 2
- 125000001845 4 membered carbocyclic group Chemical group 0.000 description 2
- NOQHUKZIZQUPLS-UHFFFAOYSA-N 4-[(3-bromo-6-chloropyridin-2-yl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound BrC=1C(=NC(=CC=1)Cl)CC1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)O NOQHUKZIZQUPLS-UHFFFAOYSA-N 0.000 description 2
- WLEYOLSIZJYNLR-UHFFFAOYSA-N 4-[(3-bromo-6-methoxypyridin-2-yl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound BrC=1C(=NC(=CC=1)OC)CC1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)O WLEYOLSIZJYNLR-UHFFFAOYSA-N 0.000 description 2
- CJUMDGADQJSSKK-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1=CC=C(Br)C=C1 CJUMDGADQJSSKK-UHFFFAOYSA-N 0.000 description 2
- UJFIYDAKNVSOJI-UHFFFAOYSA-N 4-phenylmethoxypyridine-2-carbaldehyde Chemical compound C1=NC(C=O)=CC(OCC=2C=CC=CC=2)=C1 UJFIYDAKNVSOJI-UHFFFAOYSA-N 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- MLDCBJPLHBPJET-UHFFFAOYSA-N l-687,384 Chemical compound C1CC2(C3=CC=CC=C3CCC2)CCN1CC1=CC=CC=C1 MLDCBJPLHBPJET-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- APCPBNNLVCVDPL-UHFFFAOYSA-N methyl 3-bromo-6-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=NC(Cl)=CC=C1Br APCPBNNLVCVDPL-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NOCFCCNGOFVBDJ-UHFFFAOYSA-N n-benzyl-2-bromo-n-(2-bromoethyl)ethanamine Chemical compound BrCCN(CCBr)CC1=CC=CC=C1 NOCFCCNGOFVBDJ-UHFFFAOYSA-N 0.000 description 2
- VLWJKVNMRMHPCC-UHFFFAOYSA-N n-benzyl-2-chloro-n-(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CC1=CC=CC=C1 VLWJKVNMRMHPCC-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000003616 phosphatase activity assay Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 102200155728 rs121918462 Human genes 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- KLCJQNWXKSIYTO-UHFFFAOYSA-N tert-butyl 2-hydroxyspiro[1,2-dihydroindene-3,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C1=CC=CC=C1CC2O KLCJQNWXKSIYTO-UHFFFAOYSA-N 0.000 description 2
- SRSGDDVCIMFHCR-UHFFFAOYSA-N tert-butyl 4-(1-hydroxyprop-2-enyl)-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(CC1)C(O)C=C SRSGDDVCIMFHCR-UHFFFAOYSA-N 0.000 description 2
- OLFXJXSFIXWTQG-UHFFFAOYSA-N tert-butyl 4-(2-bromopyridin-3-yl)-4-cyanopiperidine-1-carboxylate Chemical compound BrC1=NC=CC=C1C1(CCN(CC1)C(=O)OC(C)(C)C)C#N OLFXJXSFIXWTQG-UHFFFAOYSA-N 0.000 description 2
- YFYSPIRFZKBBAU-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(CO)CC1 YFYSPIRFZKBBAU-UHFFFAOYSA-N 0.000 description 2
- SSPDSPKXQMJFTD-UHFFFAOYSA-N tert-butyl 4-[(3-chloropyridin-4-yl)-hydroxymethyl]-4-methylpiperidine-1-carboxylate Chemical compound ClC=1C=NC=CC=1C(C1(CCN(CC1)C(=O)OC(C)(C)C)C)O SSPDSPKXQMJFTD-UHFFFAOYSA-N 0.000 description 2
- UBWVOABIWPXDHX-UHFFFAOYSA-N tert-butyl 4-cyano-4-(2-methylpyridin-3-yl)piperidine-1-carboxylate Chemical compound C(#N)C1(CCN(CC1)C(=O)OC(C)(C)C)C=1C(=NC=CC=1)C UBWVOABIWPXDHX-UHFFFAOYSA-N 0.000 description 2
- LMKGOFDRKIAUPZ-UHFFFAOYSA-N tert-butyl 4-formyl-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(C=O)CC1 LMKGOFDRKIAUPZ-UHFFFAOYSA-N 0.000 description 2
- LPQFKJWJZFGTOW-UHFFFAOYSA-N tert-butyl 4-prop-2-enoyl-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(CC1)C(=O)C=C LPQFKJWJZFGTOW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- LMHITKMDUAQSCH-QGZVFWFLSA-N (2R)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[3,4-dihydro-2H-naphthalene-1,4'-piperidine]-2-amine Chemical compound C1=C(C(=C(N=C1)N)Cl)SC1=NC=C(N2CCC3(CC2)C2=CC=CC=C2CC[C@H]3N)N=C1N LMHITKMDUAQSCH-QGZVFWFLSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- GZEICNCXFFBIFK-CQSZACIVSA-N (6R)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[5,6-dihydrocyclopenta[b]pyridine-7,4'-piperidine]-6-amine Chemical compound C1(=C(SC2=C(N)N=C(N3CCC4(CC3)C3=NC=CC=C3C[C@H]4N)C=N2)C=CN=C1N)Cl GZEICNCXFFBIFK-CQSZACIVSA-N 0.000 description 1
- KJOVBBYFILFNCE-QGZVFWFLSA-N (7S)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[5,7-dihydrocyclopenta[b]pyridine-6,4'-piperidine]-7-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CC1)CC=1C(=NC=CC=1)[C@H]2N)SC1=C(C(=NC=C1)N)Cl KJOVBBYFILFNCE-QGZVFWFLSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- YSEGBZPCQIJQFY-NMKYRHBASA-N (R)-N-[(1S)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-6-methoxyspiro[1,3-dihydroindene-2,4'-piperidine]-1-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@H]1C2(CCN(CC2)C2=NC(=C(SC3=CC=NC(=C3Cl)N)N=C2)N)CC2=CC=C(OC)C=C12 YSEGBZPCQIJQFY-NMKYRHBASA-N 0.000 description 1
- LUXAJVRQAXXQCW-SWOVSXPHSA-N (R)-N-[(1S)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@H]1C2(CCN(CC2)C2=NC(=C(SC3=CC=NC(=C3Cl)N)N=C2)N)CC2=CC=CC=C12 LUXAJVRQAXXQCW-SWOVSXPHSA-N 0.000 description 1
- MNTFAXBHMVOSBN-WPLJPSAOSA-N (R)-N-[(2R)-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[3,4-dihydro-2H-naphthalene-1,4'-piperidine]-2-yl]-2-methylpropane-2-sulfinamide Chemical compound C(C)(C)([S@@](=O)N[C@H]1C2(CCN(CC2)C2=NC(=C(SC3=C(C(=NC=C3)N)Cl)N=C2)N)C2=CC=CC=C2CC1)C MNTFAXBHMVOSBN-WPLJPSAOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JYTLFMXDOWJSEC-UHFFFAOYSA-N 1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-5-methylspiro[7H-cyclopenta[b]pyridine-6,4'-piperidine]-5-amine Chemical compound C1(=C(SC2=NC=C(N3CCC4(C(N)(C5=C(C4)N=CC=C5)C)CC3)N=C2N)C=CN=C1N)Cl JYTLFMXDOWJSEC-UHFFFAOYSA-N 0.000 description 1
- UVPKSKDGGBOOBS-UHFFFAOYSA-N 1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-7-methoxyspiro[1,3-dihydroindene-2,4'-piperidine]-1-amine Chemical compound C1(=C(SC2=NC=C(N3CCC4(C(C5=C(C4)C=CC=C5OC)N)CC3)N=C2N)C=CN=C1N)Cl UVPKSKDGGBOOBS-UHFFFAOYSA-N 0.000 description 1
- GSKYHGKSGOSWOG-UHFFFAOYSA-N 1'-benzyl-6-(oxan-4-yloxy)spiro[3H-indene-2,4'-piperidine]-1-one Chemical compound O=C1c2cc(OC3CCOCC3)ccc2CC11CCN(Cc2ccccc2)CC1 GSKYHGKSGOSWOG-UHFFFAOYSA-N 0.000 description 1
- WYKWUPMZBGOFOV-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-8-ol Chemical compound C1CCNC2=C1C=CC=C2O WYKWUPMZBGOFOV-UHFFFAOYSA-N 0.000 description 1
- RFYAHGIFCMOBLY-UHFFFAOYSA-N 1,2-dichloroethyl carbonochloridate Chemical compound ClCC(Cl)OC(Cl)=O RFYAHGIFCMOBLY-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- YPUQESSXEHDQFB-UHFFFAOYSA-N 1-O-tert-butyl 4-O-methyl 4-(2-methylpyridin-3-yl)piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)C1=CC=CN=C1C YPUQESSXEHDQFB-UHFFFAOYSA-N 0.000 description 1
- AHMDOYYGYISJHR-HXUWFJFHSA-N 1-[(3S)-3-amino-1'-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-5-yl]ethanone Chemical compound C1(=C(SC2=NC=C(N3CCC4([C@@H](C5=CC(=CC=C5C4)C(=O)C)N)CC3)N=C2N)C=CN=C1N)Cl AHMDOYYGYISJHR-HXUWFJFHSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- DVFVYGOJZOUJJB-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-[(4-bromophenyl)methyl]piperidine-1,4-dicarboxylate Chemical compound C=1C=C(Br)C=CC=1CC1(C(=O)OCC)CCN(C(=O)OC(C)(C)C)CC1 DVFVYGOJZOUJJB-UHFFFAOYSA-N 0.000 description 1
- BBNNLJMGPASZPD-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonylacetonitrile Chemical compound CC1=CC=C(S(=O)(=O)CC#N)C=C1 BBNNLJMGPASZPD-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- GNFWMEFWZWXLIN-UHFFFAOYSA-N 2-bromopyridine-3-carbaldehyde Chemical compound BrC1=NC=CC=C1C=O GNFWMEFWZWXLIN-UHFFFAOYSA-N 0.000 description 1
- VRMUIVKEHJSADG-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CN=C(Cl)S1 VRMUIVKEHJSADG-UHFFFAOYSA-N 0.000 description 1
- PHGXUFPYCAWEHK-UHFFFAOYSA-N 2-fluoro-3-methylpyridine Chemical compound CC1=CC=CN=C1F PHGXUFPYCAWEHK-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- HNTZKNJGAFJMHQ-UHFFFAOYSA-N 2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=CC=C1C(O)=O HNTZKNJGAFJMHQ-UHFFFAOYSA-N 0.000 description 1
- DUHQIGLHYXLKAE-UHFFFAOYSA-N 3,3-dimethylglutaric acid Chemical compound OC(=O)CC(C)(C)CC(O)=O DUHQIGLHYXLKAE-UHFFFAOYSA-N 0.000 description 1
- KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BOLCKGGORFPPJC-UHFFFAOYSA-N 3-bromo-6-chloropyrazin-2-amine Chemical compound NC1=NC(Cl)=CN=C1Br BOLCKGGORFPPJC-UHFFFAOYSA-N 0.000 description 1
- RDZPMWLHALUNCD-UHFFFAOYSA-N 3-bromo-6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(Cl)=CC=C1Br RDZPMWLHALUNCD-UHFFFAOYSA-N 0.000 description 1
- NPDICENVXROWJV-UHFFFAOYSA-N 3-chloro-2-fluoro-4-iodopyridine Chemical compound FC1=NC=CC(I)=C1Cl NPDICENVXROWJV-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- AUNJMFSHBXABDE-HXUWFJFHSA-N 4-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]pyrazin-2-yl]sulfanyl-3-chloro-1H-pyridin-2-one Chemical compound C1=C(C(=C(N=C1)O)Cl)SC1=NC=C(N2CCC3(CC2)CC2=CC=CC=C2[C@H]3N)N=C1 AUNJMFSHBXABDE-HXUWFJFHSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
- NYWOXCHAPWQNFC-UHFFFAOYSA-N 4-iodo-1h-indole-2,3-dione Chemical compound IC1=CC=CC2=C1C(=O)C(=O)N2 NYWOXCHAPWQNFC-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- ADEKJVNFIQUGRR-UHFFFAOYSA-N 4h-pyridin-3-one Chemical compound O=C1CC=CN=C1 ADEKJVNFIQUGRR-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- UJGDLLGKMWVCPT-UHFFFAOYSA-N 6-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2CCC(=O)C2=C1 UJGDLLGKMWVCPT-UHFFFAOYSA-N 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- LUFYZCHJHREYNO-KKSCSNNKSA-N C(C)(C)(C)OC(=O)N1CCC2(CC1)/C(/CC1=CC=CC=C12)=N/[S@](=O)C(C)(C)C Chemical compound C(C)(C)(C)OC(=O)N1CCC2(CC1)/C(/CC1=CC=CC=C12)=N/[S@](=O)C(C)(C)C LUFYZCHJHREYNO-KKSCSNNKSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- BULIFUCQCDBUPA-UHFFFAOYSA-N CC1(CCN(CC1)C(=O)OC(C)(C)C)CC2=C(C=NC=C2)Cl Chemical compound CC1(CCN(CC1)C(=O)OC(C)(C)C)CC2=C(C=NC=C2)Cl BULIFUCQCDBUPA-UHFFFAOYSA-N 0.000 description 1
- MSACNODAXJVUDF-UHFFFAOYSA-N CP(C)[O] Chemical compound CP(C)[O] MSACNODAXJVUDF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102100023794 ETS domain-containing protein Elk-3 Human genes 0.000 description 1
- 101100001676 Emericella variicolor andK gene Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- KNFSIUIJWFJTTB-RVXWVPLUSA-N N1N=NC2=C1C=CC=C2[C@@]2([C@H](O)[C@H](O)[C@@H](CO)O2)N2C=NC=1C(N)=NC=NC21 Chemical compound N1N=NC2=C1C=CC=C2[C@@]2([C@H](O)[C@H](O)[C@@H](CO)O2)N2C=NC=1C(N)=NC=NC21 KNFSIUIJWFJTTB-RVXWVPLUSA-N 0.000 description 1
- RLERKLCMAFLQGS-VAJZRNNVSA-N NC1=C(C=C2C=C(CC2=C1)N1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)N[S@](=O)C(C)(C)C)SC2=C(C(=NC=C2)N)Cl Chemical compound NC1=C(C=C2C=C(CC2=C1)N1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)N[S@](=O)C(C)(C)C)SC2=C(C(=NC=C2)N)Cl RLERKLCMAFLQGS-VAJZRNNVSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150036867 SYP gene Proteins 0.000 description 1
- 101800001701 Saposin-C Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102220469701 Tyrosine-protein phosphatase non-receptor type 11_F71K_mutation Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102200155471 c.182A>T Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- GILVNZWYCBUGMT-UHFFFAOYSA-N ethyl 2-chloro-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(Cl)=N1 GILVNZWYCBUGMT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220219080 rs1060503402 Human genes 0.000 description 1
- 102200155732 rs121918453 Human genes 0.000 description 1
- 102200155478 rs121918459 Human genes 0.000 description 1
- 102200155479 rs121918460 Human genes 0.000 description 1
- 102200155721 rs121918464 Human genes 0.000 description 1
- 102200155720 rs121918465 Human genes 0.000 description 1
- 102200155726 rs121918465 Human genes 0.000 description 1
- 102220056960 rs397507505 Human genes 0.000 description 1
- 102220195854 rs397507507 Human genes 0.000 description 1
- 102200155463 rs397507509 Human genes 0.000 description 1
- 102200155464 rs397507509 Human genes 0.000 description 1
- 102200155474 rs397507512 Human genes 0.000 description 1
- 102220011054 rs397507546 Human genes 0.000 description 1
- 102220050877 rs397507546 Human genes 0.000 description 1
- 102220011057 rs397507548 Human genes 0.000 description 1
- 102220053684 rs727503380 Human genes 0.000 description 1
- 102220195869 rs751437780 Human genes 0.000 description 1
- 102220115413 rs886039463 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- QXNXVWNYCKUANQ-UHFFFAOYSA-N spiro[indene-1,4'-piperidine] Chemical compound C1CNCCC21C1=CC=CC=C1C=C2 QXNXVWNYCKUANQ-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- NHHGOTWWRPGODI-KWMCUTETSA-N tert-butyl (2R)-2-[[(R)-tert-butylsulfinyl]amino]spiro[1,2-dihydroindene-3,4'-piperidine]-1'-carboxylate Chemical compound CC(C)([S@@](=O)N[C@H]1C2(C3=CC=CC=C3C1)CCN(CC2)C(=O)OC(C)(C)C)C NHHGOTWWRPGODI-KWMCUTETSA-N 0.000 description 1
- HDDUCRQHFJPZLL-KKSCSNNKSA-N tert-butyl (3Z)-3-[(R)-tert-butylsulfinyl]iminospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)[S@@](=O)/N=C\1/C2(CCN(CC2)C(=O)OC(C)(C)C)CC2=CC=CC=C/12 HDDUCRQHFJPZLL-KKSCSNNKSA-N 0.000 description 1
- MTRSMPBZKCQJCP-CAPFRKAQSA-N tert-butyl (3Z)-3-hydroxyimino-4-methoxyspiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C\12=C(OC)C=CC=C2CC2(/C/1=N/O)CCN(CC2)C(=O)OC(C)(C)C MTRSMPBZKCQJCP-CAPFRKAQSA-N 0.000 description 1
- NZJYNCPPDBQNHL-UHFFFAOYSA-N tert-butyl 1,7-dioxospiro[3H-indolizine-2,4'-piperidine]-1'-carboxylate Chemical compound C12(CCN(CC1)C(=O)OC(C)(C)C)CN1C(C2=O)=CC(=O)C=C1 NZJYNCPPDBQNHL-UHFFFAOYSA-N 0.000 description 1
- APWWBPVIUHCUSA-UHFFFAOYSA-N tert-butyl 1-amino-7-oxospiro[1,3-dihydroindolizine-2,4'-piperidine]-1'-carboxylate Chemical compound C12(CCN(CC1)C(=O)OC(C)(C)C)CN1C(C2N)=CC(=O)C=C1 APWWBPVIUHCUSA-UHFFFAOYSA-N 0.000 description 1
- MYFKCPHSMFVYTP-UHFFFAOYSA-N tert-butyl 1-methylsulfonyloxy-7-oxospiro[1,3-dihydroindolizine-2,4'-piperidine]-1'-carboxylate Chemical compound CS(=O)(=O)OC1C2=CC(C=CN2CC11CCN(CC1)C(=O)OC(C)(C)C)=O MYFKCPHSMFVYTP-UHFFFAOYSA-N 0.000 description 1
- WYDRCMKCBWMSNK-UHFFFAOYSA-N tert-butyl 3-oxospiro[1h-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(=O)C2=CC=CC=C2C1 WYDRCMKCBWMSNK-UHFFFAOYSA-N 0.000 description 1
- SSOOVSQLNXDLCV-UHFFFAOYSA-N tert-butyl 4-(3-chloropyridine-4-carbonyl)-4-methylpiperidine-1-carboxylate Chemical compound ClC1=C(C(=O)C2(CCN(CC2)C(=O)OC(C)(C)C)C)C=CN=C1 SSOOVSQLNXDLCV-UHFFFAOYSA-N 0.000 description 1
- MZQDMBLLRIEPTM-UHFFFAOYSA-N tert-butyl 4-formyl-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(C=O)CC1 MZQDMBLLRIEPTM-UHFFFAOYSA-N 0.000 description 1
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 1
- SYWYQFCUXGWVOQ-UHFFFAOYSA-N tert-butyl 5-(carbamoylamino)-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C12(CCN(CC1)C(=O)OC(C)(C)C)C(=O)C1=C(C=CC(NC(=O)N)=C1)C2 SYWYQFCUXGWVOQ-UHFFFAOYSA-N 0.000 description 1
- ITTJMBGBJNQMNH-UHFFFAOYSA-N tert-butyl 5-(dimethylcarbamoyl)-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1=C(C=CC2=C1C(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)C2)C(=O)N(C)C ITTJMBGBJNQMNH-UHFFFAOYSA-N 0.000 description 1
- TUGBXBFQDMCNDH-UHFFFAOYSA-N tert-butyl 5-(methanesulfonamido)-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound N1(CCC2(CC1)CC1=CC=C(NS(=O)(=O)C)C=C1C2=O)C(=O)OC(C)(C)C TUGBXBFQDMCNDH-UHFFFAOYSA-N 0.000 description 1
- KZVIJJLCZXFJFB-UHFFFAOYSA-N tert-butyl 5-(oxan-4-yloxy)-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(CCC21C(=O)C1=C(C=CC(OC3CCOCC3)=C1)C2)C(=O)OC(C)(C)C KZVIJJLCZXFJFB-UHFFFAOYSA-N 0.000 description 1
- FWAGBCSQMSNBOH-UHFFFAOYSA-N tert-butyl 5-amino-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound N1(CCC2(CC1)C(=O)C1=C(C=CC(N)=C1)C2)C(=O)OC(C)(C)C FWAGBCSQMSNBOH-UHFFFAOYSA-N 0.000 description 1
- MFDPPILQIZUTNQ-UHFFFAOYSA-N tert-butyl 5-cyano-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(CCC21C(=O)C1=C(C=CC(C#N)=C1)C2)C(=O)OC(C)(C)C MFDPPILQIZUTNQ-UHFFFAOYSA-N 0.000 description 1
- LOMVOFISPQZRNU-UHFFFAOYSA-N tert-butyl 5-methoxy-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C12(CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(OC)C=C1C2=O LOMVOFISPQZRNU-UHFFFAOYSA-N 0.000 description 1
- JOSTYAMUDBMADA-UHFFFAOYSA-N tert-butyl 5-methylsulfinyl-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound S(=O)(C1=CC=C2CC3(CCN(CC3)C(=O)OC(C)(C)C)C(=O)C2=C1)C JOSTYAMUDBMADA-UHFFFAOYSA-N 0.000 description 1
- IXSBSGVIPMZTNE-UHFFFAOYSA-N tert-butyl 5-morpholin-4-yl-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1N(CCOC1)C1=CC=C2C(C(=O)C3(CCN(CC3)C(=O)OC(C)(C)C)C2)=C1 IXSBSGVIPMZTNE-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- UTYXJYFJPBYDKY-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide;trihydrate Chemical compound O.O.O.[K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UTYXJYFJPBYDKY-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a novel heterocyclic derivative used as an SHP2 inhibitor, in particular to a compound shown in a structural formula I or a pharmaceutically acceptable salt thereof, and further relates to an application of the compound shown in the structural formula I or the pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof in preparing medicines, especially an application in preparing medicines for treating, preventing or preventing diseases or discomfort mediated by SHP2 activity.
Description
The application is a divisional application of an invention patent application with application date of 09.05.2018 and application number of 202011087825.3, and the invention name of the invention is 'novel heterocyclic derivative capable of being used as an SHP2 inhibitor'.
Technical Field
The present invention relates to certain novel pyrazine derivatives (as represented by structural formula I, II, III or IV) that are useful as SHP2 inhibitors, their synthesis, and their use for the treatment of SHP 2-mediated disorders. More particularly, the present invention relates to fused heterocyclic derivatives useful as SHP2 inhibitors, methods of preparing such compounds, and methods of treating SHP2 mediated diseases.
Background
SHP2 (Src homology region-2 protein tyrosine phosphatase, the Src homology-2 phosphotase) is a non-receptor protein tyrosine phosphatase encoded by ptpn11 gene, comprising a conserved tyrosine phosphatase domain, two N-terminal Src homology region 2 (SH 2) domains, and a C-terminal tail. Two SH2 domains determine the subcellular localization and functional regulation of SHP 2. In the inactive state, the N-terminal SH2 domain blocks PTP domain binding and inactivates it. When the SH2 domain binds to a specific tyrosine residue on the receptor or receptor-associated adaptor protein, the PTP domain is released and the autoamtic inhibition is released. Activation of SHP2, for example, by stimulation with cytokines and growth factors results in exposure of catalytic sites, resulting in enzymatic activation of SHP 2.
SHP2 is widely expressed and is involved in multiple cell signaling processes, such as Ras-Erk, PI3K-Akt, jak-Stat, met, FGFR, EGFR, and insulin receptor and NF-kB pathways, and plays an important role in cell proliferation, differentiation, cell cycle and migration.
The catalytically active hyperactivation of SHP2 by germline or somatic mutations has been found in Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemia, myelodysplastic syndrome, B precursor acute lymphocytic leukemia, and acute myelogenous leukemia. In addition, activating mutations of PTPN11 are also found in solid tumors, such as lung cancer, colon cancer, melanoma, neuroblastoma, and liver cancer. Thus, activated SHP2 or up-regulated SHP2 protein in human tumors or other diseases is a new therapeutic target. The compounds of the present invention satisfy the need for small molecule inhibitors of SHP 2.
Disclosure of Invention
The present invention relates to heterocyclic pyrazine compounds which are inhibitors of SHP2 useful in the treatment of diseases mediated by SHP 2. The invention firstly provides a compound shown as a general formula I and pharmaceutically acceptable salts thereof:
wherein:
each R 1 Are all independently selected from-H, halogen, -NH 2 CN, -substituted or unsubstituted-C 1-6 Alkoxy, or substituted or unsubstituted-C 1-6 An alkyl group;
R 2 selected from-H, halogen, -NH 2 、-CN、-OH、-NHC 1-6 Alkyl, -N (C) 1-6 Alkyl radical) 2 Substituted or unsubstituted-C 1-6 Alkoxy, substituted or unsubstituted-C 1-6 Alkyl or-C 5-10 A heterocyclic group; or
R 2 To adjacent R 1 Are linked together with the carbon atom to which they are each attached to form a 6-10 membered aromatic ring, a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring and each ring system independently may be optionally substituted or substituted with 1,2 or 3 halogen, -NH 2 、-CN、-C 1-6 Alkyl or-CO-C 1-6 Alkyl substitution;
each Y 1 Independently selected from N or CH;
R 3 is selected from-H or-NH 2 ;
Each R 4a And R 4b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy or-C 1-6 An alkyl group; or
R 4a And R 4b Together with the carbon atoms to which they are commonly attached form CO, C = NH, or C = N-OH;
p is 0, 1,2 or 3;
each R 5a And R 5b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy or-C 1-6 An alkyl group; or
R 5a And R 5b Together with the carbon atom to which they are both attached, form a 3-5 membered heterocyclyl or C = NH;
q is 0, 1,2,3 or 4;
w is absent, O, S or NR w (ii) a And R is w is-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-6 alkyl-O-C 1-6 Alkoxy, substituted or unsubstituted-C 1-6 Alkoxy, or substituted or unsubstituted-C 1-6 An alkyl group;
ring A is absent or is a 3-10 membered ring;
when ring A is absent, Y 2 Is CR 2a R 2b 、NR 2a Or O, and Y 3 Is CR 3a R 3b 、NR 3a Or O;
when ring A is a 3-to 10-membered ring:
each R 2a 、R 2b 、R 3a And R 3b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, substituted or unsubstituted-C 1-6 Alkoxy, or substituted or unsubstituted-C 1-6 An alkyl group;
each R 6 Independently selected from-H, halogen, -NR 6a R 6b 、-CN、-OH、-NO 2 Oxo group, = O, carboxy group, -C 1-6 Alkoxy, -C 1-6 Alkyl, -C 1-6 alkenyl-NR 6a R 6b 、-C 1-6 alkenyl-O-C 1-6 Alkyl, -C 1-6 Alkenyl, -CO-OR 6a 、-C 1-6 alkenyl-C 3-10 Heterocyclyl radical, -C 1-6 alkenyl-C 5-10 Heteroaryl, -C 1-6 alkenyl-CO-NR 6a R 6b 、-C 1-6 alkenyl-NR 6a -CO-NR 6a R 6b 、-C 1-6 alkenyl-NR 6a -CO-C 1-6 Alkyl, -CO-NR 6a R 6b 、-CO-CO-NR 6a R 6b 、-C 3-10 Carbocyclyl, -C 3-10 Heterocyclyl, -CO-C 1-6 Alkyl, -CO-C 1-6 alkenyl-NR 6a R 6b 、-CO-NR 6a -C 3-10 heterocyclyl-CO-NR 6a -C 3-10 Heterocyclyl, -CO-C 3-10 Heterocyclyl, -O-C 1-6 alkenyl-CO-OR 6a 、-O-C 1-6 alkenyl-CO-NR 6a R 6b 、-O-C 1-6 alkenyl-NR 6a R 6b 、-O-C 3-10 Carbocyclyl, -O-C 3-10 Heterocyclyl radical, -NR 6a -CO-C 1-6 Alkyl, -NR 6a -CO-NR 6a R 6b 、-NR 6a -CO-C 5-10 Heteroaryl, -NR 6a -C 1-6 olefin-NR 6a R 6b 、-NR 6a -C 1-6 olefin-C 3-10 Heterocyclyl radical, -NR 6a -C 1-6 olefin-C 5-10 Heteroaryl, -NR 6a -SO 2 C 1-6 Alkyl, -S-C 1-6 Alkyl, -SONR 6a R 6b 、-SO 2 NR 6a R 6b 、-SO-C 1-6 Alkyl, -SO 2 C 1-6 Alkyl, -PO (C) 1-6 Alkyl radical) 2 、-PO(C 1-6 Alkoxy group) 2 、-C 3-10 Heterocyclyl or-C 5-10 A heteroaryl group; each R 6 Each independently optionally substituted or unsubstituted with 1,2 or 3 substituents; and n is 0, 1,2,3,4, 5 or 6; or
Two adjacent R 6 Are connected together and with themThe carbon atoms to which they are respectively attached together form a 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-6 Heterocyclic radicals or C 3-6 Carbocyclyl, and each ring system independently is optionally substituted or unsubstituted with one or more substituents;
each R 6a And R 6b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, substituted or unsubstituted-C 1-6 Alkoxy, or substituted or unsubstituted-C 1-6 An alkyl group.
The present invention further provides some preferred embodiments for the compounds of formula I.
A compound of the general formula (I) or a pharmaceutically acceptable salt thereof, 2. Each R 1 Independently selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; -C 1-6 An alkyl group; -C 1-6 An alkoxy group; by 1,2 or 3 halogens, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkyl or-C 1-3 Alkoxy substituted-C 1-6 An alkyl group; or by 1,2 or 3 halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkyl or-C 1-3 alkoxy-substituted-C 1-6 An alkoxy group.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 1 Independently selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; a methyl group; an ethyl group; a propyl group; isopropyl group; a methoxy group; an ethoxy group; a propoxy group; an isopropoxy group; by 1,2 or 3-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy substituted-C 1-3 An alkyl group; or by 1,2 or 3 of-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 C substituted by carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy 1-3 An alkoxy group.
In some embodiments, the compounds of formula (I)A compound of the formula or a pharmaceutically acceptable salt thereof, each R 1 Independently selected from-H; -F; -Cl; -Br; -NH 2 (ii) a -CN; -OH; a methyl group; an ethyl group; a propyl group; an isopropyl group; a methoxy group; an ethoxy group; a propoxy group; an isopropoxy group; or methyl substituted with 1,2 or 3 substituents, and each substituent is independently selected from-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, or isopropoxy.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, R 2 Is selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 ;-N 3 (ii) a A carboxyl group; -C 1-3 An alkyl group; -C 1-3 An alkoxy group; -NHC 1-3 An alkyl group; -N (C) 1-3 Alkyl radical) 2 ;-CONH 2 ;-CONHC 1-3 An alkyl group; -CON (C) 1-3 Alkyl radical) 2 ;-COC 1-3 An alkyl group; -NHCOC 1-3 An alkyl group; -N (C) 1-3 Alkyl) -CO-C 1-3 An alkyl group; -C 5-10 A heterocyclic group; is substituted by 1,2 or 3 substituents selected from-F, -Cl, -Br, -I, -NH 2 -C substituted by a substituent of-CN or-OH 1-3 An alkyl group; or is substituted by 1,2 or 3 groups selected from-F, -Cl, -Br, -I, -NH 2 -C substituted by a substituent of-CN or-OH 1-3 An alkoxy group.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, R 2 Is selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 ;-N 3 (ii) a A carboxyl group; a methyl group; an ethyl group; propyl; isopropyl group; a methoxy group; an ethoxy group; a propoxy group; an isopropoxy group; -NHCH 3 ;-N(CH 3 ) 2 ;-CONH 2 ;-CONHCH 3 ;-CON(CH 3 ) 2 ;-COCH 3 ;-NH-COCH 3 ;-N(CH 3 )-COCH 3 ;Or methyl or ethyl substituted by 1,2 or 3 substituents selected from-F,-Cl、-Br、-NH 2 -CN or-OH.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, R 2 R adjacent thereto 1 Are linked and taken together with the carbon atom to which they are each linked to form a 5-membered heteroaryl, 6-membered aryl, 5-membered heterocyclyl or 6-membered heterocyclyl; and each said heteroaryl or heterocyclyl group contains 1 or 2 heteroatoms selected from N or O; and each said ring system is independently optionally substituted by-F, -Cl, -Br, -I, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 Substituted or unsubstituted C 1-3 Alkoxy, substituted or unsubstituted C 1-3 Alkyl, -C 1-3 alkenyl-O-C 1-3 Alkyl, -C 1-3 alkenyl-COOH, -C 1-3 alkenyl-NHCONH 2 、-CO-N(C 1-3 Alkyl radical) 2 、-C 1-3 alkenyl-NHCO-C 1-3 Alkyl, -CO-CO-N (C) 1-3 Alkyl radical) 2 、-CO-C 1-3 Alkyl, -SONH 2 、-SO 2 NH 2 、-SOCH 3 or-SO 2 CH 3 Substituted or unsubstituted.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, R 2 R adjacent thereto 1 Are linked and taken together with their respective linking carbon atoms to form a 5-membered heteroaryl, 6-membered aryl, 5-membered heterocyclyl or 6-membered heterocyclyl; and each heteroaryl or heterocyclyl group contains 1 heteroatom selected from N or O; and each said ring system may be independently optionally substituted by-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 Methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -CH 2 OCH 3 、-CH 2 COOH、-CH 2 NHCONH 2 、-CON(CH 3 ) 2 、-CH 2 NHCOCH 3 、-CO-CON(CH 3 ) 2 or-COCH 3 Substituted or unsubstituted.
In some embodiments, the compounds of formula (I)A compound of the formula R 2 R adjacent thereto 1 Are bound and form together with the carbon atoms to which they are respectively bound
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 4a And R 4b Are independently selected from-H, -F, -Cl, -Br, -I and-NH 2 、-CN、-OH、-NO 2 Carboxy or-C 1-3 An alkyl group; or
R 4a And R 4b Together with the carbon atoms to which they are commonly attached, form C = O, C = NH, or C = N-OH.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 4a And R 4b Are all independently selected from-H, -NH 2 -OH, methyl, ethyl, methoxy or ethoxy; or
R 4a And R 4b Together with the carbon atoms to which they are commonly attached, form C = O.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 5a And R 5b Are each independently selected from-H; -F; -Cl; -Br; -I; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; -C 1-3 An alkyl group; -C 1-3 An alkoxy group; is substituted by-F, -Cl, -Br, -I, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkyl or-C 1-3 alkoxy-substituted-C 1-6 An alkyl group; or by-F, -Cl, -Br, -I, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkyl or-C 1-3 alkoxy-substituted-C 1-6 An alkoxy group; or
R 5a And R 5b Together with the carbon atom to which they are commonly attached form C = NH, a 3-membered heterocyclyl group, a 4-membered heterocyclyl group, or a 5-membered heterocyclyl group; and each of said heterocyclyl groups independently optionally includes 1 or 2 heteroatoms selected from N or O; and each said ring system may independently optionally be-H、-F、-Cl、-Br、-I、-NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkoxy or-C 1-3 Alkyl is substituted or unsubstituted.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 5a Or R 5b Are all independently selected from-H, -NH 2 -OH, methyl, ethyl, methoxy or ethoxy; or
R 5a And R 5b Together with the carbon atom to which they are commonly attached, form C = NH, a 3-membered heterocyclyl, a 4-membered heterocyclyl, or a 5-membered heterocyclyl; and each of said heterocyclyl groups contains 1 heteroatom selected from N or O.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof, W is NR w And R is w Selected from-H, -F, -Cl, -Br, -I, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 alkyl-O-C 1-3 Alkyl, -C 1-3 Alkoxy or-C 1-3 An alkyl group.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, W is NR w And R is w Selected from-H, -F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, methyl-CO-methyl or methyl-CO-methoxy.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof, ring a is selected from 6-membered aryl, 10-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, 10-membered heteroaryl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 7-membered heterocyclyl, 8-membered heterocyclyl, 9-membered heterocyclyl, 10-membered heterocyclyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 7-membered carbocyclyl, 8-membered carbocyclyl, 9-membered carbocyclyl, or 10-membered carbocyclyl; and each heteroaryl or each heterocyclyl independently optionally contains 1,2 or 3 heteroatoms selected from N, O or S.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof, ring a is selected from 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 7-membered heterocyclyl, 8-membered heterocyclyl; a 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, or 8-membered carbocyclic group; and each heteroaryl and each heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N, O or S.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof, ring A is selected from
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 2a 、R 2b 、R 3a And R 3b Are all independently selected from-H, -F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkyl or-C 1-3 An alkoxy group.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 2a 、R 2b 、R 3a And R 3b Are all independently selected from-H, -F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy.
In some embodiments, a compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, R 2a And R 2b Each independently is-H or methyl, and R 3a And R 3b Each independently is-H.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 6 Are all independently selected from-H, -F, -Cl, -Br, -NR 6a R 6b -CN, -OH, oxo, = O, carboxy, -C 1-3 Alkoxy, -C 1-4 Alkyl, -C 1-3 alkenyl-NR 6a R 6b 、-C 1-3 alkenyl-O-C 1-3 Alkyl, -C 1-3 alkenyl-CO-OR 6a 、-C 1-3 alkenyl-C 5-6 Heterocyclyl radical, -C 1-3 alkenyl-C 5-6 Heteroaryl, -C 1-3 alkenyl-CO-NR 6a R 6b 、-C 1-3 Alkenyl, -NR 6a -CO-NR 6a R 6b 、-CO-NR 6a R 6b 、-CO-CO-NR 6a R 6b 、-CO-C 1-3 Alkyl, -CO-NR 6a -C 5-6 Heterocyclyl, -CO-C 5-6 Heterocyclyl, -O-C 5-6 Carbocyclyl, -O-C 5-6 heterocyclyl-NR 6a -CO-C 1-3 Alkyl, -NR 6a -CO-NR 6a R 6b 、-NR 6a -C 1-3 alkenyl-NR 6a R 6b 、-NR 6a -C 1-6 alkenyl-C 3-6 Heterocyclyl radical, -NR 6a -SO 2 C 1-3 Alkyl, -S-C 1-3 Alkyl, -SO-C 1-3 Alkyl, -SO 2 NR 6a R 6b 、-SO 2 C 1-3 Alkyl, -PO (C) 1-3 Alkyl radical) 2 、-PO(C 1-3 Alkoxy group) 2 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered heteroaryl or 6-membered heteroaryl, and each R 6 Independently optionally substituted or unsubstituted with 1,2 or 3 substituents selected from-F, -Cl, br, -NH 2 -OH, carboxyl, oxo, = O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; each R is 6a And R 6b Are each independently selected from-H; -F; -Cl; br; i; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; -C 1-3 An alkoxy group; -C 1-3 Alkyl radicals or substituted by 1,2 or 3-H, halogen, -NH 2 -CN or-OH substituted-C 1-3 An alkyl group; or
Two adjacent R 6 Taken together and together with the carbon atoms to which they are each attached form a 6-membered aryl, 5-membered carbocyclyl, 5-membered heteroaryl, or 5-membered heterocyclyl; and each of said heteroaryl or heterocyclyl groups contains 1 or 2 heteroatoms selected from N, O or S; and each said ring system is independently optionally substituted or unsubstituted with 1,2 or 3 substituents, each said substituent being independently selected from-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 - = O, oxo, carboxy, -CONH 2 、-PO(CH 3 ) 2 Methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, or isopropoxy.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 6 Are each independently selected from-H; -F; -Cl; -Br; -NR 6a R 6b (ii) a -CN; -OH; an oxo group; = O; a carboxyl group; a methoxy group; an ethoxy group; propoxy group; an isopropoxy group; a methyl group; an ethyl group; propyl; isopropyl group; a tertiary butyl group; -C 1-3 alkenyl-NR 6a R 6b ;-NR 6a -CO-NR 6a R 6b ;-CO-NR 6a R 6b ;-CO-CO-NR 6a R 6b (ii) a -CO-methyl; -CO-ethyl; -CO-NR 6a -C 5-6 A heterocyclic group; -CO-C 5-6 A heterocyclic group; -O-C 5-6 A carbocyclic group; -O-C 5-6 A heterocyclic group; -NR 6a -CO-methyl; -NR 6a -CO-NR 6a R 6b ;-NR 6a -C 1-3 alkenyl-NR 6a R 6b ;-NR 6a -C 1-6 alkenyl-C 3-6 A heterocyclic group; -NR 6a -SO 2 -a methyl group; -NR 6a -SO 2 -an ethyl group; -S-methyl; -S-ethyl; -SO-methyl; -SO-ethyl; -SO 2 NR 6a R 6b ;-SO 2 A methyl group; -SO 2 An ethyl group; -PO (methyl) 2 (ii) a -PO (ethyl) 2 (ii) a -PO (methoxy) 2 (ii) a -PO (ethoxy) 2 (ii) a A 5-membered heterocyclyl containing 1,2 or 3 heteroatoms; containing 1,2 or 3 hetero atomsAn atomic 6-membered heterocyclic group; a 5-membered heteroaryl group containing 1,2 or 3 heteroatoms; or a6 membered heteroaryl group containing 1,2 or 3 heteroatoms selected from N, O or S; wherein each R 6 Each independently optionally substituted or unsubstituted with 1,2 or 3 substituents selected from-F, -Cl, br, -NH 2 -OH, carboxyl, oxo, = O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; each R 6a And R 6b Are each independently selected from-H; -F; -Cl; br; i; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; a methyl group; an ethyl group; a methoxy group; an ethoxy group; by 1,2 or 3 of-H, F, cl, br, -NH 2 -CN or-OH substituted methyl; or by 1,2 or 3 of-H, F, cl, br, -NH 2 Ethyl substituted by-CN or-OH; or
Two adjacent R 6 Taken together and together with the carbon atoms to which they are each attached form a phenyl, 5-membered carbocyclyl, 5-membered heteroaryl containing 1 or 2N or O, or 5-membered heterocyclyl containing 1 or 2N or O; and each said ring system is independently optionally substituted or unsubstituted with 1,2 or 3 substituents, each said substituent being independently selected from-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 - = O, oxo, carboxy, -CONH 2 、-PO(CH 3 ) 2 Methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, or isopropoxy.
In some embodiments, a compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, each R 6 Are independently selected from-F, -Cl, -Br, = O, -OH, -CN, -NH 2 、-SCH 3 、-SOCH 3 、-SO 2 CH 3 、-PO(CH 3 ) 2 、-PO(OC 2 H 5 ) 2 、-NHSO 2 CH 3 、-C(O)NH 2 Methyl, ethyl, isopropyl, methoxy, ethoxy, = O, oxo, -OH, -CN, -NH 2 、-Cl、-Br、-CF 3 、-OCF 3 、-SO 2 NH 2 、-SO 2 CH 3 、-CH 2 NH 2 、-SCH 3 、 -NHCOCH 3 、/>-NHCONHCH 3 、/> Or
Two adjacent R 6 Are linked together and form together with the carbon atoms to which they are respectively attached
In some embodiments, the compound of the general formula shown in structural formula (I), or a pharmaceutically acceptable salt thereof, is a compound shown in structural formula II:
wherein:
R 3 is selected from-H or-NH 2 ;
Each R 4a Or R 4b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy or substituted or unsubstituted-C 1-3 An alkyl group; or
R 4a And R 4b Together with the carbon atom to which they are both attachedForm C = O, C = NH, or C = N-OH;
p is 0, 1,2 or 3;
each R 5a Or R 5b Are all independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy or substituted or unsubstituted-C 1-3 An alkyl group; or
R 5a And R 5b Together with the carbon atom to which they are both attached form a 3-5 membered heterocyclyl; and each of said heterocyclyl groups is independently optionally substituted or unsubstituted with 1,2 or 3 substituents selected from-H, halogen, -NH 2 -CN or-OH;
q is 0, 1,2,3 or 4;
ring A is a 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl;
R 2a selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy or substituted or unsubstituted-C 1-3 An alkyl group;
each R 6 Independently selected from-H, halogen, -NR 6a R 6b 、-CN、-OH、-NO 2 Oxo, = O, carboxy, -C 1-3 Alkoxy, -C 1-4 Alkyl, -CO-NR 6a R 6b 、-CO-CO-NR 6a R 6b 、-CO-C 1-3 Alkyl, -CO-NR 6a -C 3-10 heterocyclyl-CO-NR 6a -C 3-10 Heterocyclyl, -CO-C 4-6 Heterocyclyl, -O-C 3-6 Carbocyclyl, -O-C 3-6 Heterocyclyl radical, -NR 6a -CO-C 1-3 Alkyl, -NR 6a -CO-NR 6a R 6b 、-NR 6a -CO-C 5-6 Heteroaryl, -NR 6a -SO 2 C 1-3 Alkyl, -S-C 1-3 Alkyl, -SONR 6a R 6b 、-SO 2 NR 6a R 6b 、-SO-C 1-3 Alkyl, -SO 2 -C 1-3 Alkyl, -PO (C) 1-3 Alkyl radical) 2 、-PO(C 1-3 Alkoxy group) 2 、-C 3-6 Heterocyclyl or-C 5-6 Heteroaryl, wherein each R 6 Each independently optionally substituted with 1,2 or 3 substituents or unsubstituted; and n is 0, 1,2 or 3; or
Two adjacent R 6 Taken together with the carbon atoms to which they are respectively attached to form a 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-6 Heterocyclyl or C 3-6 Carbocyclyl, each said ring system being independently optionally substituted or unsubstituted with 1,2 or 3 substituents;
each R 6a And R 6b Independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxyl, or substituted or unsubstituted-An alkyl group.
In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt thereof, each R 5a Or R 5b Independently selected from-H, -Cl, -Br, -NH 2 -OH, carboxyl, methyl, ethyl, methoxy or ethoxy; or
R 5a And R 5b Together with the carbon atom to which they are jointly attached formAnd C represents said carbon atom and R 5a And R 5b And (4) connecting.
In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt thereof, ring a is 6-membered phenyl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, 9-membered heteroaryl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, or 6-membered carbocyclyl; and each heteroaryl group independently comprises 1 or 2 heteroatoms selected from N, O or S; each of said heterocyclyl groups independently contains 1 or 2 heteroatoms selected from N or O.
In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt thereof, ring A is selected from/>
In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt thereof, R 2a Is selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; a methyl group; an ethyl group; propyl; isopropyl group; a methoxy group; an ethoxy group; a propoxy group; an isopropoxy group; is-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy substituted-C 1-3 An alkyl group; or by-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy substituted-C 1-3 An alkoxy group.
In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt thereof, Y 2 Is CH or N, and Y 3 Is CH or N.
In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt thereof, Y 2 Is C, and Y 3 Is C.
In some techniquesIn the scheme, a compound of the general formula shown in the structural formula (II) or a pharmaceutically acceptable salt thereof, each R 6 Are all independently selected from-H, -F, -Cl, -Br, -NH 2 、-N(CH 3 ) 2 -CN, -OH, oxo, = O, carboxy, methoxy, ethoxy, methyl, ethyl, isopropyl, tert-butyl, -CH 2 NH 2 、-CH 2 CH 2 OCH 3 、-CH 2 -COOH、-CH 2 NH-CONHCH 3 、-CONH 2 、-CON(CH 3 ) 2 、-CONHOH、-CONHCH 2 CH 2 OH、-CO-CON(CH 3 ) 2 、-COCH 3 、-SO 2 NH 2 、-SO 2 CH 3 、-SCH 3 、-SOCH 3 、-PO(CH 3 ) 2 、-PO(OC 2 H 5 ) 2 、-NHSO 2 CH 3 、-NH-COCH 3 、-NH-CONHCH 3 、
Wherein each R 6 Independently optionally substituted by 1,2 or 3-F, -Cl, -NH 2 -OH, oxo, = O, methyl, ethyl or propyl substituted or unsubstituted.
In some embodiments, a compound of the general formula shown in structural formula (II), or a pharmaceutically acceptable salt thereof, each R 6a And R 6b Are all independently selected from-H, -Cl, -Br and-NH 2 -OH, carboxyl, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, methyl substituted with-OH or ethyl substituted with-OH.
In some embodiments, the compound of the general formula shown in structural formula (I) or a pharmaceutically acceptable salt thereof, is a compound shown in structural formula (III):
wherein:
each R 1 And R 2 Are all independently selected from-H, -F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkoxy or-C 1-3 An alkyl group; or
R 1 R adjacent thereto 2 Are linked and together with the carbon atom to which they are each attached form a 5-membered heterocyclic ring containing 1,2 or 3 heteroatoms selected from N or O, and said 5-membered heterocyclic ring is optionally substituted with 1,2 or 3 halogens, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 or-CO-C 1-3 Alkyl substituted or unsubstituted;
Y 1 is selected from N or CH;
R 3 is selected from-H or-NH 2 ;
Ring B is selected from a benzene ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-membered carbocyclic ring, a 4-membered carbocyclic ring, a 5-membered carbocyclic ring, a 6-membered carbocyclic ring, a 5-membered heterocyclic ring or a 6-membered heterocyclic ring, and each of said heteroaromatic ring groups or heterocyclic rings independently optionally comprises 1 or 2 heteroatoms selected from N or O;
R 7 selected from halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 、-NH-COCH 3 Substituted or unsubstituted-C 1-6 Alkoxy, or substituted or unsubstituted-C 1-6 An alkyl group; and m is 0, 1 or 2.
In some embodiments, the compound of formula (I) orA pharmaceutically acceptable salt thereof, R 1 R adjacent thereto 2 Are linked and form together with the carbon atoms to which they are respectively linkedAnd said ring system is independently optionally substituted by 1 or 2-F or-COCH 3 Substituted or unsubstituted.
In some embodiments, the compound of formula (III) or a pharmaceutically acceptable salt thereof, and ring B is selected from
In some embodiments, a compound of the general formula shown in structural formula (III), or a pharmaceutically acceptable salt thereof, R 7 Is selected from-NH 2 CN, oxo, = O, -CONH 2 、-NH-COCH 3 Methyl or methoxy.
In some embodiments, the compound of the general formula (I) or a pharmaceutically acceptable salt thereof, is a compound of the structural formula (IV):
wherein:
each R 1 And R 2 Are each independently selected from-H; -F; -Cl; -Br; -NH 2 ;-CN;-OH;-NO 2 (ii) a A carboxyl group; -NHC 1-3 An alkyl group; -N (C) 1-3 Alkyl radical) 2 ;-C 1-3 An alkoxy group; -C 1-3 Alkyl or 1,2 or 3 halogen substituted-C 1-3 An alkyl group; or
R 1 R adjacent thereto 2 Are linked and taken together with the carbon atom to which they are each attached form a 6-membered carbocyclic ring, a 6-membered aryl ring, a 5-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N or O, or a 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N or O, and each of said ring systems is independently optionally substituted with 1,2 or 3 halogens, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 、-C 1-3 Alkoxy radical,-C 1-3 Alkyl or-CO-C 1-3 Alkyl substituted or unsubstituted;
Y 1 is N or CH;
R 3 is-H or-NH 2 ;
Ring D is selected from 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl, each of said heteroaryl or heterocyclyl independently optionally containing 1 or 2 heteroatoms selected from N, O or S;
each R 2a And R 3a Are each independently selected from-H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkoxy or-C 1-3 An alkyl group;
R 8 selected from halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, C 1-4 Alkyl radical, C 1-3 Alkoxy, -SO 2 NR 8a R 8b 、-S-C 1-3 Alkyl, -SO-C 1-3 Alkyl, -SO 2 -C 1-3 Alkyl, -CO-NR 8a R 8b 、-PO(C 1-3 Alkyl radical) 2 、-PO(C 1-3 Alkoxy group) 2 、-NR 8a -CO-C 1-3 Alkyl, -NR 8a -CO-NR 8a R 8b -O-5 membered carbocyclyl, -O-5 membered heterocyclyl, -O-6 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 5 membered heteroarylOr 6-membered heteroaryl; and each R 8 Each independently optionally substituted by 1,2 or 3 substituents selected from halogen, methyl, ethyl, methoxy, oxo, -NH 2 A substituent of-CN or-OH is substituted or unsubstituted; and t is 0, 1,2 or 3; or
Two adjacent R 8 Taken together with the carbon atoms to which they are respectively attached to form a 6-membered aryl or 5-membered heteroaryl group, and each of said ring systems is independently optionally substituted or unsubstituted;
each R 8a And R 8b Are all independently selected from H, halogen, -NH 2 、-CN、-OH、-NO 2 Carboxy, -C 1-3 Alkoxy or-C 1-3 An alkyl group.
In some embodiments, a compound of the general formula shown in structural formula (IV), or a pharmaceutically acceptable salt thereof, each R 1 And R 2 Are all independently selected from-H, -F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 、-CF 3 Carboxy, -NHCH 3 、-N(CH 3 ) 2 Methoxy, ethoxy, methyl or ethyl; or
R 1 R adjacent thereto 2 Are linked and taken together with the carbon atom to which they are each attached form a 6-membered carbocyclic ring, a 6-membered aryl group, a 5-membered heterocyclic group containing 1 heteroatom selected from N or O, or a 5-membered heteroaromatic ring including 1 heteroatom selected from N or O; and each said ring system is independently optionally substituted with 1,2 or 3 substituents selected from-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, -CONH 2 Methoxy, ethoxy, methyl, ethyl, -CO-methyl or-CO-ethyl.
In some embodiments, the compound of formula (IV), or a pharmaceutically acceptable salt thereof, each R 1 And R 2 Are all independently selected from-H, -F, -Cl, -Br and-NH 2 、-CN、-OH、-NO 2 、-CF 3 Carboxy, -NHCH 3 、-N(CH 3 ) 2 Methoxy, ethoxy, methyl or ethyl; or
R 1 R adjacent thereto 2 Are connected and respectively connected with themThe carbon atoms bound together formingAnd each of said ring systems is independently optionally substituted with 1,2 or 3 substituents selected from-F or-COCH 3 Substituted or unsubstituted.
In some embodiments, the compound of formula (IV) or a pharmaceutically acceptable salt thereof, and ring D is selected from/>
In some embodiments, the compound of formula (IV), or a pharmaceutically acceptable salt thereof, each R 2a And R 3a Are each independently selected from-H, methyl or methoxy.
In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt thereof, R 8 Selected from-F, -Cl, -Br, -NH 2 、-CN、-OH、-NO 2 Carboxy, oxo, = O, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, -CO-methyl, -SO 2 NR 8a R 8b -S-methyl, -S-ethyl, -SO-methyl, -SO-ethyl, -SO 2 -methyl, -SO 2 -ethyl, -CO-C 3-6 heterocyclyl-CO-NR 8a R 8b -PO (methyl) 2 -PO (ethyl) 2 -PO (methoxy) 2 -PO (ethoxy) 2 、-NR 8a -CO-methyl, -NR 8a -CO-ethyl, -NR 8a -CO-NR 8a R 8b 、-NR 8a -SO 2 Methyl, -O-5 membered carbocyclyl, -O-5 membered heterocyclyl, -O-6 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 5 membered heteroaryl or 6 membered heteroaryl, each of which is heteroCyclyl or heteroaryl contains 1 or 2 heteroatoms selected from O, N or S; each R 8 Independently optionally substituted by 1,2 or 3 substituents selected from-F, -Cl, -Br, -NH 2 -CN, -OH, oxo, = O, methoxy, ethoxy, methyl or ethyl.
In some embodiments, a compound of the general formula shown in structural formula (IV) or a pharmaceutically acceptable salt thereof, R 8 Selected from-F, -Cl, -Br, -NH 2 CN, -OH, carboxyl, oxo, = O, methyl, ethyl, isopropyl, tert-butyl, CF 3 Methoxy, -SOCH 3 、-SO 2 CH 3 、-SCH 3 、P(O)(CH 3 ) 2 、P(O)(OC 2 H 5 ) 2 、NHS(O) 2 CH 3 、-CONH 2 、-NH-COCH 3 、-NH-CONHCH 3 、-NH-COCH 3 、
In some embodiments, a compound of the general formula shown by structural formulae (I), (II), (III) (IV), or a pharmaceutically acceptable salt thereof, is:
in another aspect, the present invention further provides a pharmaceutical composition, comprising at least one compound represented by formula (I), (II), (III) or (IV) of the present invention or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
Further, in the pharmaceutical composition, the weight ratio of the compound shown in structural formula (I), (II), (III) or (IV) or the pharmaceutically acceptable salt thereof to the auxiliary material is 0.0001-10.
In another aspect, the invention also provides the use of the pharmaceutical composition for the preparation of a medicament.
In some embodiments, the medicament is for treating, preventing, or preventing a disease or disorder mediated by SHP2 activity.
In some embodiments, the disease or disorder mediated by SHP2 activity is cancer, cancer metastasis, cardiovascular disease, immune disorders, fibrosis, or vision disorders.
In some embodiments, the disease or disorder mediated by SHP2 activity is selected from one or more of the following conditions: noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myelogenous leukemia, breast cancer, esophageal tumor, lung cancer, colon cancer, head cancer, stomach cancer, lymphoma, glioblastoma, stomach cancer, pancreatic cancer, and combinations thereof.
The term "halogen" as used herein means, unless otherwise specified, fluorine, chlorine, bromine or iodine. Preferably, halogens include fluorine, chlorine and bromine. The term "halo C 1-6 Alkyl group "," halogeno C 2-6 Alkenyl group "," halogeno C 2-6 Alkynyl "and" halo C 1-6 Alkoxy "means an alkoxy group in which one or more (especially 1,2 or 3) hydrogen atoms are replaced by a halogen atom, especially a fluorine or chlorine atom. In some embodiments, fluoro C is preferred 1-6 Alkyl, fluoro C 2-6 Alkenyl, fluoro C 2-6 Alkynyl and fluoro C 1-6 Alkoxy, especially fluoro C 1-3 Alkyl radicals, e.g. CF 3 、CHF 2 、CH 2 F、CH 2 CH 2 F、CH 2 CHF 2 、CH 2 CF 3 (ii) a Fluoro C 1-3 Alkoxy radicals, e.g. OCF 3 、OCHF 2 、OCH 2 F、OCH 2 CH 2 F、OCH 2 CHF 2 Or OCH 2 CF 3 (ii) a In particular CF 3 、OCF 3 And OCHF 2 。
Unless otherwise stated, it is to be understood that,the alkyl group in the present invention includes a saturated monovalent hydrocarbon group having a straight chain, branched chain or cyclic moiety. For example, alkyl includes methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-methylpentyl and cyclohexyl. Similarly, in the present invention C 1-8 Alkyl is defined as a group having 1,2,3,4, 5,6, 7 or 8 carbon atoms in a linear or branched arrangement.
Alkylene means a bifunctional group obtained by removing a hydrogen atom from an alkyl group as defined above. For example, methylene (i.e., -CH) 2 -, ethylene (i.e. -CH) 2 -CH 2 -or-CH (CH) 3 ) -) and propylene (i.e., -CH 2 -CH 2 -CH 2 -,-CH(-CH 2 -CH 3 ) -or-CH 2 -CH(CH 3 )-)。
Alkoxy is an oxygen ether formed from a straight, branched or cyclic alkyl group as described above.
The term "aryl" as used herein by itself or as part of another substituent means, unless otherwise stated, a monocyclic or polycyclic aromatic hydrocarbon. Phenyl and naphthyl are preferred aryl groups. The most preferred aryl group is phenyl.
As used herein, unless otherwise specified, the term "heterocycle" by itself or as part of another substituent refers to an unsubstituted and substituted mono-or polycyclic non-aromatic, partially unsaturated or fully saturated ring system containing one or more heteroatoms. Preferred heteroatoms include N, O and S, including N-oxides, sulfur oxides and dioxides. Preferably the ring is three to eight membered and is fully saturated or has one or more unsaturations. Included in this definition are a plurality of degrees of substitution, preferably one, two or three degrees of substitution.
Examples of such heterocyclyl groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, azepanyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl sulfoxide, oxadiazole, or oxaza.
As used herein, unless otherwise specified, the term "heteroaryl" by itself or as part of another substituent refers to an aromatic ring system containing carbon and at least one heteroatom. Heteroaryl groups may be monocyclic or polycyclic, substituted or unsubstituted. Monocyclic heteroaryl groups may have 1 to 4 heteroatoms in the ring, while polycyclic heteroaryl groups may contain 1 to 10 heteroatoms. The polycyclic heteroaryl ring may contain a fused spiro or bridged ring, for example, the cyclic heteroaryl is a polycyclic heteroaryl. A bicyclic heteroaryl ring may contain 8 to 12 member atoms. Monocyclic heteroaryl rings may contain 5 to 8 member atoms (carbon number and heteroatoms). Examples of heteroaryl groups include, but are not limited to, thienyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyladenosine, quinolinyl, or isoquinolinyl.
As used herein, unless otherwise specified, the term "cycloalkyl" by itself or as part of another substituent means a substituted or unsubstituted monocyclic, bicyclic or polycyclic non-aromatic saturated or partially unsubstituted hydrocarbon group, which optionally includes an alkylene linker through which the cycloalkyl group may be attached. Exemplary "cycloalkyl" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
The term "oxo" refers to the group = O.
The term "oxo" or "= O" means that it forms C = O together with the carbon atom to which it is attached.
Whenever the term "alkyl" or "aryl" or any of its prefix roots appears in the name of a substituent (e.g., aralkyl or dialkylamino), by itself or as part of another substituent, unless otherwise stated, it should be construed as including the limitations given above for "alkyl" and "aryl". The specified number of carbon atoms (e.g., cl-6) shall independently refer to the number of carbon atoms in the alkyl portion or the number of carbon atoms in the alkyl portion of the larger substituent for which the alkyl is the prefix.
Two "R" in the general formula I, II, III or IV 1 The substituents of "may be the same or different. Similar to "R 1 ", and two" Y's of the formula I, II, III or IV 1 The "may be the same or different.
The compounds described herein, e.g., certain compounds of formula I, II, III or IV, may contain asymmetrically substituted carbon atoms (or chiral centers) in the R or S configuration. The present invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
The compounds described herein, when specifically designated by chemical name as the R-or S-isomer, should be understood as having the R-or S-isomer, respectively, as the predominant configuration. For example, in any of the embodiments described herein, such R-or S-designated isomer may be substantially free (e.g., less than 5%, less than 1%, or undetectable by chiral HPLC) of another isomer at each chiral center. The R-or S-isomer can be prepared by the methods exemplified herein, for example, by using a chiral auxiliary such as R-or S-tert-butylsulfinamide during the synthesis. Other methods of preparing the dominant R-or S-isomer herein include, but are not limited to, chiral HPLC purification of a mixture of stereoisomers (e.g., a racemic mixture). General methods for separating stereoisomers (e.g., enantiomers and/or diastereomers) using HPLC are known in the art.
The compounds described herein may exist in isotopically labeled or enriched forms, containing one or more atoms with an atomic mass or mass number different from the atomic mass or mass number most abundant in nature. The isotope may be a radioactive or non-radioactive isotope. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 32P, 35S, 18F, 36C1, and 125I. Compounds containing other isotopes of these and/or other atoms are within the scope of the present invention. In some embodiments, one or more hydrogen atoms of any of the compounds described herein can be replaced with deuterium to provide a corresponding labeled or enriched compound.
As used herein, the term "subject" (alternatively referred to as "patient" in the present invention) refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
As used herein, unless otherwise indicated, the term "ring system" (which may also be referred to as "ring system") includes, but is not limited to, carbocyclic rings, heterocyclic rings, heteroaromatic rings, and the like, and may also include only heterocyclic rings and/or heteroaromatic rings, and specifically includes which rings are determined as the context requires, but in any case "ring system" does not include C-based 1-6 Alkyl or C 1-3 Cycloalkyl radicals of alkyl radicals and not including radicals based on C 1-6 Alkoxy or C 1-3 An alkoxy group.
The compounds of the general formula I, II, III or IV can have different isomeric forms. For example, any asymmetric carbon atom may be present in the (R) -, (S) -or (R, S) -configuration, preferably in the (R) -or (S) -configuration. The double bonds or especially the substituents on the ring can be present in cis (= Z-) or trans (= E-) form. These compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as pure diastereomers or pure enantiomers.
When used in the plural (e.g., compound, salt), it includes the singular (e.g., single compound, single salt). "Compound" does not exclude the presence (e.g. in a pharmaceutical preparation) of more than one compound of formula I, II, III or IV (or a salt thereof), "a" merely standing for the indefinite article. Thus "a" may preferably be understood as "one or more", and should not be understood as "a"
"SHP2" refers to "Src homology-2-containing protein tyrosine phosphatase", also known as SH-PTP2, SH-PTP3, syp, PTP1D, PTP2C, SAP-2, or PTPN11.
Cancers that carry "PTPNll mutations" include, but are not limited to: N58Y; D61Y, V; E69K; A72V, T, D; E76G, Q, K (ALL); G60A; D61Y; E69V; F71K; A72V; T73I; E76G, K; R289G; G503V (AML); G60R; D61Y, V, N; Y62D; E69K; A72T, V; T73I; E76K, V, G, A, Q; el39D; G503A, R; Q506P (JMML); G60V; D61V; E69K; F71L; A72V; E76A (MDS); Y63C (CMML); Y62C; E69K; T507K (neuroblastoma); V46L; N58S; E76V (lung cancer); R138Q (melanoma); E76G (colon cancer).
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the invention as active ingredients and processes for preparing the compounds of the invention are also part of the invention. In addition, some of the crystalline forms of the compounds of the present invention may exist as polymorphs and as such are included in the present invention. In addition, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also included within the scope of the present invention.
The compounds of the invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, salts of the compounds of the invention refer to non-toxic "pharmaceutically acceptable salts". Pharmaceutically acceptable salts include pharmaceutically acceptable acidic/anionic or basic/cationic salts. Pharmaceutically acceptable acidic/anionic salts generally take the form in which a basic nitrogen is protonated by an inorganic or organic acid, representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, isethionic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclamic, salicylic, saccharin or trifluoroacetic acid. Pharmaceutically acceptable basic/cationic salts include, but are not limited to, aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium, and zinc.
Prodrugs of the compounds of the invention are also included within the scope of the invention. Typically, such prodrugs are functional derivatives of the compounds of the present invention which are readily convertible in vivo into the desired compound. Thus, in the methods of treatment of the present invention, the term "administering" shall include the use of the compounds of the present invention specifically disclosed, as well as the use of compounds that may not be specifically disclosed, but which may be converted in vivo to the specified compound after administration to a patient for the treatment of various conditions or disorders. Conventional methods for selecting and preparing suitable prodrugs are described, for example, prodrug design, published in 1985 by h.
In the present invention, the definition of any substituent or variable at a particular position is independent of the definition of that substituent or variable at other positions in the molecule. It is to be understood that substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and can be readily synthesized by techniques known in the art and those methods set forth herein.
The compounds encompassed by the present invention may contain one or more asymmetric centers and thus may give rise to diastereomers and optical isomers. The present invention includes all those possible diastereoisomers as well as their racemic mixtures, their substantially pure, resolved enantiomers, all possible geometric isomers and pharmaceutically acceptable salts thereof.
The above formulae I, II, III or IV do not indicate stereochemistry determined at a specific position. The present invention includes all stereoisomers of formula I, II, III or IV and pharmaceutically acceptable salts thereof. In addition, mixtures of stereoisomers as well as isolated, defined stereoisomers are also included. The products of these processes may be mixtures of stereoisomers during the synthetic procedures used to prepare these compounds, or during the use of racemization or epimerization procedures known to those skilled in the art.
When tautomers exist for compounds of formula I, II, III or IV, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, unless otherwise specified.
When a compound of formula I, II, III or IV, and pharmaceutically acceptable salts thereof, are present in solvate, or polymorphic, forms, the present invention includes any possible solvate and polymorphic form. The kind of the solvent forming the solvate is not particularly limited as long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone, or the like can be used.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compounds of the invention are acidic, their corresponding salts may be conveniently prepared from pharmaceutically acceptable non-toxic bases including inorganic and organic bases. When the compounds of the present invention are basic, their corresponding salts may be conveniently prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Since the compounds of formula I, II, III or IV are for pharmaceutical use, they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, especially at least 98% pure (% on a weight basis).
The pharmaceutical composition of the present invention comprises a compound represented by formula I, II, III or IV (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include those suitable for oral, rectal, topical and parenteral (including subcutaneous, intramuscular and intravenous) administration, although the most suitable route in any given case will depend on the particular subject and the nature and severity of the condition to which the active ingredient is being administered. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
In practice, the compounds represented by formula I, II, III or IV or prodrugs or metabolites thereof or pharmaceutically acceptable salts thereof as active ingredients of the present invention may be combined with a pharmaceutical carrier in intimate admixture according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention may be presented as discrete units suitable for oral administration, for example, as capsules, cachets (cachets) or tablets each containing a predetermined amount of the active ingredient. Furthermore, the composition may be in the form of a powder, granules, a solution, a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. In addition to the above-mentioned conventional dosage forms, the compound represented by formula I, II, III or IV or a pharmaceutically acceptable salt thereof may be administered through a controlled release device and/or a delivery device. The composition may be prepared by any pharmaceutical method. Generally, these methods include the step of bringing into association the active ingredient with the carrier which contains one or more required ingredients. Typically, the compositions are prepared by uniformly and intimately admixing (unifonm and inteimately admixing) the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired form.
Accordingly, the pharmaceutical compositions of the present invention may include a pharmaceutically acceptable carrier and a compound or pharmaceutically acceptable salt of formula I, II, III or IV. The compounds of formula I, II, III or IV or pharmaceutically acceptable salts thereof may also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
The pharmaceutical carrier used may be, for example, a solid, liquid or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Examples of liquid carriers are syrup, peanut oil, olive oil and water. Examples of gas carriers include carbon dioxide and nitrogen. In preparing the compositions for oral dosage form, any convenient pharmaceutical medium may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations (e.g., suspensions, elixirs (elixirs), and solutions); while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used to form oral solid preparations (e.g., powders, capsules and tablets). Because of their ease of administration, tablets and capsules are the preferred oral dosage units, whereby solid pharmaceutical carriers are employed. Optionally, the tablets may be coated by standard aqueous or non-aqueous techniques.
Tablets containing the composition of the invention may be prepared by compression or molding, optionally together with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be prepared by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient, and each cachet or capsule preferably contains from about 0.05mg to about 5g of the active ingredient. For example, a formulation intended for oral administration to humans may contain from about 0.5mg to about 5g of the active agent, in admixture with a suitable and convenient amount of carrier material, which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms generally contain between about 1mg to about 2g of active ingredient, typically 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or l000mg.
Pharmaceutical compositions of the invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compound in water. Suitable surfactants may comprise, for example, hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. In addition, preservatives may be included to prevent the unwanted growth of microorganisms.
Pharmaceutical compositions of the invention suitable for injectable use include sterile aqueous solutions or dispersions. In addition, the compositions may be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injection must be sterile and must be an effective liquid to facilitate injection. The pharmaceutical composition must be stable under the conditions of manufacture and storage; it is therefore preferred that the contaminating action of microorganisms such as bacteria and fungi should be prevented. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
The pharmaceutical compositions of the present invention may be in a form suitable for topical use, such as aerosols, creams, ointments, lotions, dusting powders (dusting powders) and the like. Further, the composition may be in a form suitable for use in a transdermal device. These formulations can be prepared by conventional processing methods using the compounds represented by formula I, II, III or IV of the present invention or pharmaceutically acceptable salts thereof. For example, a cream or ointment is prepared by mixing a hydrophilic material and water with about 5% to about 10% by weight of the compound to produce a cream or ointment having a desired consistency.
The pharmaceutical compositions of the invention may be in a form suitable for rectal administration and the carrier is a solid. Preferably, the mixture forms a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories may conveniently be formed by first mixing the composition with the softened or molten carrier, followed by cooling and shaping in moulds.
In addition to the above-described carrier ingredients, the above-described pharmaceutical formulations may optionally include one or more additional carrier ingredients, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), and the like. In addition, other adjuvants may be included to make the formulation isotonic with the blood of the target recipient. Compositions containing a compound described by formula I, II, III or IV, or a pharmaceutically acceptable salt thereof, may also be prepared in the form of a powder or liquid concentrate.
In general, dosage levels of from about 0.01mg/kg body weight to about 150mg/kg body weight per day, or alternatively from about 0.5mg to about 7g per patient per day, may be employed to treat the above conditions. For example, inflammation, cancer, psoriasis, allergy/asthma, diseases and disorders of the immune system, diseases and disorders of the Central Nervous System (CNS) can be effectively treated by administering about 0.01 to 50mg of the compound per kilogram of body weight per day, or about 0.5mg to about 3.5g of the compound per patient per day.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
These and other aspects will become apparent from the following written description of the invention.
Examples
The following intermediates and examples are provided to illustrate the present invention. Unless otherwise expressly indicated, all parts and percentages are by weight and all temperatures are in degrees Celsius. The following abbreviations are used in the examples:
intermediate A1
To a solution of 6-methoxy-2, 3-dihydro-1H-inden-1-one (1.50g, 9.25mmol) in DMF (10 mL) under nitrogen was added sodium hydride (60% dispersion in mineral oil, 1.11g, 27.75mmol) portionwise. The mixture was heated to 60 ℃ and stirred at this temperature for 20 minutes. Tert-butyl bis (2-chloroethyl) carbamate (2.46g, 10.17mmol) was added dropwise and the mixture was stirred for 85min. After cooling to RT, the reaction was diluted with EA (200 mL), washed with brine (3X 200 mL) and the organic phase was washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 12,v/v) to give 6-methoxy-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine as a yellow solid]-1'-Tert-butyl carboxylate (557 mg). MS M/z 332 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 1
Intermediate A2
Step a: diethanolamine (198.15g, 1.88mol), K 2 CO 3 A mixture of (520.95g, 3.77mol), benzyl bromide (386.79g, 2.26mol) and acetonitrile (2000 mL) was stirred at 90 ℃ for 2.5h. After cooling to RT, filtration and rinsing of the filter cake with EA (2X 100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) to give N-benzyldiethanolamine (89.44 g) as a colorless oil. MS: M/z 196 (M + H) + .
Step b: phosphorus tribromide (69.13g, 0.26mol) was added dropwise to a 0 ℃ solution of N-benzyldiethanolamine (30.66g, 0.16mol) in toluene (300 mL). The system was warmed to 105 ℃ and stirred for 16h. After cooling to RT, the volatiles were removed by concentration under reduced pressure. The residue was diluted with water (300 mL) and the pH adjusted to 9 with NaOH. The system was extracted with EA (3X 150 mL), the organic phases were combined and washed with anhydrous Na 2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure to give N-benzyl-2-bromo-N- (2-bromoethyl) ethan-1-amine (41.58 g), which was used in the next step without any further purification. MS M/z 320 (M + H) + .
Step c: under nitrogen atmosphere, to 0 deg.C 6, 7-dihydro-5H-cyclopenta [ b ]]To a solution of pyridin-5-one (1.70g, 12.77mmol) in DMF (20 mL) was added sodium hydride (60% dispersion in mineral oil, 982mg, 24.55mmol) in three portions, and the mixture was heated to 60 deg.C and stirred at this temperature for 1h. N-benzyl-2-bromo-N- (2-bromoethyl) ethan-1-amine (4.54g, 14.14mmol) was then added and stirred for a further 1h at 60 ℃. After cooling to RT, the reaction was quenched with water (80 mL),extract with EA (3X 80 mL). The combined organic phases were washed with water (3X 80 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give 1' -benzylspiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-5 (7H) -one (1.14 g). MS: M/z 293 (M + H) + .
Step d: to 0 ℃ of 1' -benzylspiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]To a solution of-5 (7H) -one (1.05g, 3.59mmol) in DCE (10 mL) was added dropwise chloro-1-chloroethyl chloroformate (903mg, 6.32mmol). The system was stirred at RT for 1.5h. The volatiles were removed by concentration under reduced pressure and the residue was dissolved in MeOH (20 mL) and stirred at 80 ℃ for 4h. The volatiles were removed by concentration under reduced pressure and the residue was dissolved in DCM (20 mL). DIEA (1.33g, 10.32mmol) and (Boc) were added 2 O (1.38g, 6.32mmol). The resulting solution was stirred at RT for 16h. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 1,v/v) to give 5-oxo-5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (438 mg). MS: M/z 303 (M + H) + .
Intermediate A3
A, step a: LDA (2M THF/Hex solution, 24mL, 48.00mmol) was added dropwise to a-70 deg.C solution of 1-tert-butyl 4-piperidine-1, 4-dicarboxylate (8.14g, 31.64mmol) in THF (80 mL) under a nitrogen atmosphere. After the resulting solution was stirred at this temperature for 70min, 1-bromo-4- (bromomethyl) benzene (7.91g, 31.64mmol) was added in portions. The resulting solution was stirred at-70 ℃ for 3h, then carefully quenched with saturated ammonium chloride solution (50 mL). The separated aqueous phase was extracted with EA (1X 80 mL), the organic phases were combined and dried over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give 1-tert-butyl 4- (4-bromobenzyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (14.55 g) as a brown oil, which was used in the next step without any further purification. MS M/z 426 (M + H) + .
Step b: 4- (4-bromobenzyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (14.55g, 34.13mmol), naOH (8.12g, 203.00m)mol), meOH (80 mL), and water (80 mL) were stirred at 75 deg.C for 16.5h. After cooling to RT, the volatiles were removed by concentration under reduced pressure. The system was extracted with EA (3X 80 mL). The combined organic phases were washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give 4- (4-bromobenzyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid (16.87 g) which was used in the next step without any further purification. MS M/z 398 (M + H) + .
Step c: a mixture of 4- (4-bromobenzyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid (16.87g, 42.36mmol) and PPA (60 mL) was stirred at 120 ℃ for 30min. The reaction was poured into an ice-water mixture (300 mL) and the pH was adjusted to 10 with NaOH. Then add (Boc) 2 O (13.86g, 63.53mmol) and stirred at RT for 18h. The reaction was extracted with EA (3X 150 mL). The combined organic phases were freed from Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (16.87 g) -1' -carboxylate, which was used in the next step without any further purification. MS M/z 380 (M + H) + .
The following compounds were synthesized using the above procedure or modified procedure and the corresponding starting materials.
TABLE 2
Intermediate A4
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (2.06g, 5.42mmol), pd (PPh) 3 ) 4 A mixture of (626 mg, 0.54mmol), DBU (252mg, 1.66mmol), t-BuOH (15 mL), water (15 mL) and potassium ferrocyanide trihydrate (1.16g, 2.75mmol) was stirred at 90 ℃ for 22.5h. After cooling to RT, the mixture was diluted with EA (30 mL), filtered and the filter cake rinsed with EA (15 mL). The filtrate was washed with brine (1X 30 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. Disabled personThe residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give 6-cyano-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (1.86 g). MS: M/z 327 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 3
Intermediate A5
Reacting 4-cyano-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]A mixture of tert-butyl (1' -carboxylate) (0.93g, 2.85mmol), KOH (1.60g, 28.50mmol), meOH (15 mL) and water (15 mL) was stirred at 100 ℃ for 2h. After cooling to RT, the reaction mixture was diluted with water (30 mL) and extracted with EA (60mL, 30mL). The combined organic phases were washed with brine (1X 80 mL) and anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 4-carbamoyl-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (1.04 g) -1' -carboxylate was used in the next step without any further purification. MS M/z 345 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 4
Intermediate A6
To 6-carbamoyl-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (1.57g, 4.56mmol) of (E) -1' -carboxylate in DMF (15 mL) was added sodium hydride (60% dispersion in mineral oil, 0.91g, 22.79mmol), thenPost addition of CH 3 I (1mL, 16.06mmol). The system was stirred at RT for 17h. The reaction was quenched with brine (50 mL) and extracted with EA (2X 50 mL). The combined organic phases were washed with brine (1X 100 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex = 13,v/v) to give 6- (dimethylcarbamoyl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (0.82 g). MS M/z 373 (M + H) + .
Intermediate A7
Step a-c: step (a-c) Using intermediate A3 gave 1'- (tert-butyloxycarbonyl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-6-carboxylic acid. MS M/z 346 (M + H) + .
Intermediate A8
To a 50mL sealed tube was added 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (998mg, 2.62mmol), DMSO (8 mL), water (4 mL), cuI (217mg, 1.14mmol) and ammonium hydroxide (25%, 4 mL). The system was stirred at 100 ℃ for 5 days. After cooling to RT, the reaction was diluted with brine (20 mL) and EA (30 mL). Separating the organic phase with anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 6-amino-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (750 mg). MS M/z 317 (M + H) + .
Intermediate A9
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (531mg, 1.40mmol), methanesulfonamide (371mg, 3.90mmol), K 2 CO 3 (1.10g, 7.95mmol), N, N' -bisA mixture of methyl-1, 2-ethylenediamine (85mg, 0.96mmol), cuI (72mg, 0.38mmol) and 1, 4-dioxane (20 mL) was stirred at 110 ℃ for 23h. Further, methanesulfonamide (370mg, 3.89mmol), N, N' -dimethyl-1, 2-ethylenediamine (85mg, 0.96mmol) and CuI (75mg, 0.39mmol) were added, and stirring was continued at the same temperature for 7 hours. After cooling to RT, the reaction was quenched with water (30 mL) and extracted with EA (3X 50 mL). The combined organic phases are passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex = 23,v/v) to give 6- (methylsulfonylamino) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (562 mg). MS: M/z 395 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 5
Intermediate A10
To 6-amino-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (1' -carboxylate) (0.66g, 2.09mmol) in AcOH (5 mL) and water (10 mL) was added dropwise a solution of sodium cyanate (0.28g, 4.31mmol) in water (2 mL). The system was stirred at 50 ℃ for 4h. After cooling to RT, the reaction was adjusted to pH 12 with aqueous ammonia (25%) and extracted with DCM (60mL, 30mL). The combined organic phases were washed with brine (1X 60 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =2, 1,v/v) to give 1-oxo-6-ureido-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (0.39 g). MS: M/z 360 (M + H) + .
Intermediate A11
To 0 ℃ 6- (methylthio) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (336mg, 0.97mmol) of-1' -carboxylate in MeOH (20 mL) and water (20 mL) was added potassium peroxymonosulfate (296mg, 1.76mmol). The system was stirred at 0 ℃ for 1h. Saturated Na for reaction solution 2 S 2 O 3 Quench (10 mL) and concentrate under reduced pressure to remove volatiles. The system was extracted with EA (3X 40 mL) and the combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex = 41,v/v) to give 6- (methylsulfinyl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (285 mg). MS M/z 364 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 6
Intermediate A12
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.51g, 3.97mmol), dimethyl-phosphorus oxide (503mg, 6.44mmol), pd (OAc) 2 (92mg,0.41mmol),Xantphos(457mg,0.79mmol),K 3 PO 4 A mixture of (1.57g, 7.40mmol) and DMF (30 mL) was stirred at 130 ℃ for 16.5h. After cooling to RT, the reaction was quenched with water (120 mL) and extracted with EA (3X 80 mL). The combined organic phases were washed with brine (1X 120 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) to give 6- (dimethylphosphoryl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine as a white solid]-1' -carboxylic acid tert-butyl ester (0.81 g). MS M/z 378 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 7
Intermediate A13
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.09g, 2.87mmol), 1H-imidazole (180mg, 2.64mmol), cuBr (34mg, 0.24mmol), cs 2 CO 3 (851mg, 2.61mmol), a mixture of 1,2,3, 4-tetrahydro-8-hydroxyquinoline (74mg, 0.49mmol) and DMSO (10 mL) was stirred at 110 ℃ for 23h. After cooling to RT, the reaction was quenched with water (30 mL) and extracted with EA (1X 40 mL). The organic phase is treated with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give 6- (1H-imidazol-1-yl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine as a yellow solid]-1' -carboxylic acid tert-butyl ester (142 mg). MS M/z 368 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 8
Intermediate A14
1'- (tert-butyloxycarbonyl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]6-carboxylic acid (345mg, 1.00mmol), piperidine (129mg, 1.51mmol) and HATU (422mg, 1.11mmol) were stirred in DMF for 1h. The reaction was diluted with water (30 mL) and EA (30 mL). The organic phase was separated, washed with brine (1X 30 mL), and dried over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 1-oxo-6- (piperidine-1-carbonyl) -13-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (380 mg). MS M/z 413 (M + H) + .
Intermediate A15
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.02g, 2.68mmol), morpholine (0.67g, 7.69mmol), cu (OAc) 2 A mixture of (0.51g, 2.81mmol), DBU (1.03g, 6.77mmol) and DMSO (10 mL) was stirred at 130 ℃ for 23h. After cooling to RT, the reaction was diluted with water (70 mL) and extracted with EA (3X 50 mL). The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (with EA: hex =1, v/v elution) to give 6-morpholino-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (467 mg). MS M/z 387 (M + H) + .
Intermediate A16
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (500mg, 1.31mmol), 1-methylpiperazine (270mg, 2.70mmol), cs 2 CO 3 (1306mg,4.01mmol),Pd 2 (dba) 3 A mixture of (66mg, 0.07mmol), xantPhos (75mg, 0.13mmol) and 1, 4-dioxane (18 mL) was stirred at 100 ℃ for 0.5h. After cooling to RT, the reaction was quenched with water and extracted with EA (2X 100 mL). The combined organic phases were washed with brine (1X 100 mL) and anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 6- (4-methylpiperazin-1-yl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (0.87 g, crude) 1' -carboxylate, was used in the next step without any further purification. MS M/z 400 (M + H) + .
Intermediate A17
Step a: LDA (2M solution in THF/Hex, 45.00mL, 90.00mmol) was added dropwise to a-60 deg.C solution of 1-tert-butyl 4-ethyl piperidine-1, 4-dicarboxylate (15.52g, 60.31mmol) in THF (100 ml) under nitrogen. The system is naturally heated to-20 ℃ and stirred for 50min, then cooled to-50 ℃, and CH is dripped 3 I (8.56g, 60.31mmol) in THF (20 mL). Then stirred at this temperature for 50min. The reaction was carefully quenched with saturated ammonium chloride (80 mL) and extracted with EA (100mL, 50mL). The combined organic phases were washed with anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave 4-methylpiperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (17.70 g) which was used in the next step without any further purification. MS: M/z 216 (M + H-56) + .
Step b: to a 0 deg.C solution of 4-methylpiperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (17.70g, 65.23mmol) in THF (150 mL) was added LiBH 4 (2M in THF, 98.00mL, 196.00mmol). The system was stirred at 70 ℃ for 18h. After cooling to RT, quench dropwise with water (100 mL). The system was extracted with EA (200mL, 100mL), the combined organic phases were washed with brine (1X 200 mL), anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give tert-butyl 4- (hydroxymethyl) -4-methylpiperidine-1-carboxylate (12.90 g), which was used in the next step without any further purification. MS M/z 174 (M + H-56) + .
Step c: to a solution of oxalyl chloride (10.71g, 84.38mmol) in DCM (150 mL) at-78 deg.C was added dropwise a solution of DMSO (10.99g, 140.63mmol) in DCM (30 mL) and stirred at that temperature for 30min. A solution of tert-butyl 4- (hydroxymethyl) -4-methylpiperidine-1-carboxylate (12.90g, 56.25mmol) in DCM (30 mL) was added dropwise and stirred at-78 ℃ for 30min. Triethylamine (22.77g, 225.02mmol) was added dropwise, then the temperature was naturally raised to-20 ℃ and stirred for 40min. The reaction was quenched with water (80 mL). The organic phase was collected and the aqueous phase was extracted with DCM (1X 80 mL). The combined organic phases were washed with brine (1X 200 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 20,v/v) to give 4-formyl-4-methylPiperidine-1-carboxylic acid tert-butyl ester (11.82 g). MS: M/z 172 (M + H-56) + .
Step d: LDA (2M solution in THF/Hex, 11.00mL, 22.00mmol) was added dropwise to a-70 deg.C solution of 3-chloropyridine (2.25g, 17.64mmol) in THF (50 mL). The system was warmed to-60 ℃ and stirred for 1.5h. A solution of tert-butyl 4-formyl-4-methylpiperidine-1-carboxylate (3.95g, 17.37mmol) in THF (10 mL) is added dropwise at-70 ℃. After stirring for 1h, the mixture was quenched with water (50 mL). The organic phase was collected and the aqueous phase was separated and extracted with EA (60mL, 30mL). The combined organic phases were washed with brine (1X 80 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give tert-butyl 4- ((3-chloropyridin-4-yl) (hydroxy) methyl) -4-methylpiperidine-1-carboxylate (8.10 g), which was used in the next step without any purification. MS: M/z 341 (M + H) + .
Step e: to a solution of tert-butyl 4- ((3-chloropyridin-4-yl) (hydroxy) methyl) -4-methylpiperidine-1-carboxylate (8.10g, 23.76mmol) in DCM (50 ml) was added dess-martin oxidant (20.12g, 47.44mmol). The system was stirred at RT for 16h. The reaction was diluted with DCM (100 mL) and saturated Na 2 S 2 O 3 (25%, 1X 80 mL), saturated NaHCO 3 (1X 80 mL) and brine (1X 100 mL). The organic phase is passed through anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 3,v/v) to give 4- (3-chloroisonicotinyl) -4-methylpiperidine-1-carboxylic acid tert-butyl ester (4.81 g). MS M/z 339 (M + H) + .
Step f: under a nitrogen atmosphere, 4- (3-chloroisonicotinoyl) -4-methylpiperidine-1-carboxylic acid tert-butyl ester (6.31g, 18.62mmol), cs 2 CO 3 (6.72g, 21.90mmol), pivalic acid (571mg, 5.60mmol), pd (OAc) 2 (0.22g,0.98mmol),Cy 3 PH·BF 4 A mixture of (0.70g, 1.90mmol) and 1,3, 5-trimethylbenzene (40 mL) was stirred at 140 ℃ for 72h. After cooling to RT, filtration was followed by EA (3X 40 mL) rinsing. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 1,v/v) to give 5-oxo-5, 7-dihydrospiro [ cyclopenta [ c]Pyridine-6, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (2.82 g). MS: M/z 303 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 9
Intermediate A18
A, step a: to a solution of 3-bromo-6-chloropyridine-2-carboxylic acid (9.98g, 42.21mmol) in MeOH (100 mL) was added H dropwise 2 SO 4 (98%, 10.00 mL). Stirring was carried out at 70 ℃ for 3h. After cooling to RT, the pH of the reaction was adjusted to 9 by adding ammonia (25%). The volatiles were removed by concentration under reduced pressure. The mixture was diluted with water (60 mL) and extracted with EA (1X 100 mL). The organic phase was washed with brine (1X 60 mL) and anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave methyl 3-bromo-6-chloropyridine-2-carboxylate (10.14 g) as an off-white solid. MS M/z 250 (M + H) + .
Step b: to a 0 deg.C solution of methyl 3-bromo-6-chloropyridine-2-carboxylate (10.14g, 40.48mmol) in MeOH (150 mL) was added NaBH in portions 4 (4.62g, 122.13mmol). The temperature was raised to RT naturally and stirred for 16h. The reaction was diluted with brine (110 mL) and concentrated under reduced pressure to remove MeOH. Extracting with EA (100mL, 80mL), and mixing the organic phase with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give (3-bromo-6-chloropyridin-2-yl) methanol (8.31 g). MS M/z 222 (M + H) + .
Step c: to a solution of (3-bromo-6-chloropyridin-2-yl) methanol (8.31g, 37.35mmol) and triethylamine (7.63g, 75.40mmol) in DCM (100 mL) at-15 deg.C was added MsCl (4.71g, 41.12mmol) dropwise. The mixture was warmed to RT and stirred for 2h. The reaction was quenched with water (50 mL) and the aqueous phase was separated. The organic phase was washed with brine (1X 50 mL) and anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave methanesulfonic acid (3-bromo-6-chloropyridin-2-yl) methyl ester (8.54 g). MS M/z 300 (M + H) + .
Step d: LDA (2M solution of THF/Hex, 23.00mL, 46.00mmol) was added dropwise to a-50 deg.C solution of 1-tert-butyl 4-piperidine-1, 4-dicarboxylate (9.66g, 37.54mmol) in THF (30 mL) under a nitrogen atmosphere. Stirring was carried out at this temperature for 1h. A solution of methanesulfonic acid (3-bromo-6-chloropyridin-2-yl) methyl ester (8.54g, 28.41mmol) in THF (15 mL) was added dropwise, warmed to RT naturally and stirred for 1h. The reaction was quenched with brine (60 mL) and extracted with EA (1X 30 mL). The organic phase is passed through anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave 4- ((3-bromo-6-chloropyridin-2-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (17.73 g) which was used in the next step without further purification. MS: M/z 461 (M + H) + .
Step e: a mixture of 4- ((3-bromo-6-chloropyridin-2-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (17.73g, 38.39mmol), naOH (8.03g, 200.75mmol), meOH (100 mL), and water (20 mL) was stirred at 65 ℃ for 16h. After cooling to RT, the volatiles were removed by concentration under reduced pressure and the system was diluted with water (150 mL). The pH was adjusted to 6 with a saturated citric acid solution. Extracted with EA (2X 100 mL), and the combined organic phases washed with brine (1X 100 mL), anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give a mixture of 4- ((3-bromo-6-chloropyridin-2-yl) methyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid and 4- ((3-bromo-6-methoxypyridin-2-yl) methyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid (18.24 g). MS M/z 433 (M + H) + ,MS:m/z 429(M+H) + .
Step f: to a solution of a mixture of 4- ((3-bromo-6-chloropyridin-2-yl) methyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid and 4- ((3-bromo-6-methoxypyridin-2-yl) methyl) -1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid (3.80g, 8.76mmol) in THF (20 mL) at-15 deg.C was added sodium hydride (60% dispersion in mineral oil, 0.42g, 10.50mmol) in portions under a nitrogen atmosphere. After stirring at this temperature for 1h, the mixture was cooled to-60 ℃. N-alpha-olefin is added dropwise to the mixtureBuLi (2.5M Hex solution, 5mL, 12.50mmol) was then stirred for 1h. The reaction was quenched with water (20 mL) and extracted with EA (1X 40 mL). The organic phase was washed with brine (1X 30 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA: hex =1, 10,v/v) to give 2-chloro-5-oxo-5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester and 2-methoxy-5-oxo-5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester mixture (1.48 g). MS M/z 337 (M + H) + .MS:m/z 333(M+H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 10
Intermediate A19
A, step a: LDA (2M solution in THF/Hex, 6.00mL, 12.00mmol) was added dropwise to a solution of piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (2.83g, 11.00mmol) in THF (50 mL) at-78 deg.C under a nitrogen atmosphere. Stirring was carried out at this temperature for 1h. 2-chloro-5- (chloromethyl) thiazole (dissolved in 3mL THF, 1.69g, 10.06mmol) was added dropwise and stirred for 1h. The reaction was quenched with brine (50 mL) and extracted with EA (2X 30 mL). The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 20,v/v) to give 4- ((2-chlorothiazol-5-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (1.15 g). MS M/z 389 (M + H) + .
Step b: LDA (2M solution in THF/Hex, 3.00mL, 6.00mmol) was added dropwise to a-78 deg.C solution of 4- ((2-chlorothiazol-5-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (900mg, 2.31mmol) in THF (50 mL) under a nitrogen atmosphere. After stirring for 30min, quench with brine (30 mL). Extract with EA (2X 30 mL)Collecting, mixing organic phases, and adding anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 2-chloro-4-oxo-4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (832 mg). MS: M/z 343 (M + H) + .
Intermediate A20
Step a: to a solution of 2-methylnicotinic acid (4.56g, 33.25mmol) in THF (50 mL) at 0 deg.C was added LAH (1.51g, 39.90mmol). The mixture was warmed to RT and stirred for 4h. The reaction was carefully diluted with saturated ammonium chloride (50 mL). Filtering, separating filtrate, and collecting organic phase with anhydrous Na 2 SO 4 Dried, filtered again, and the filtrate was concentrated under reduced pressure to give (2-methylpyridin-3-yl) methanol (1.42 g) as a yellow oil. MS: M/z 124 (M + H) + .
Step b: to a solution of (2-methylpyridin-3-yl) methanol (1.41g, 11.45mmol) in DCM (20 mL) at 0 deg.C was added PBr dropwise 3 (1.86g, 6.87mmol). The system was warmed to RT and stirred for 1.5h. NaOH aqueous solution (5M, 10 mL) was added to adjust the pH of the reaction mixture to 8. The aqueous phase was separated and the organic phase was washed with brine (1X 20 mL) and anhydrous Na 2 SO 4 Dried and concentrated under reduced pressure to give 3-bromomethyl-2-methylpyridine (3.52 g) as a yellow oil, which was used in the next step without further purification. MS M/z 186 (M + H) + .
Step c: to a solution of piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (4.63g, 18.00mmol) at-50 ℃ in THF (30 mL) was added LDA (2M solution in THF/Hex, 12.00mL, 24.00mmol) dropwise, stirring at this temperature for 1h. 3-bromomethyl-2-methylpyridine (3.25g, 18.00mmol) was added, the temperature was raised to RT naturally and stirring was carried out for 16h. Saturated NH for reaction solution 4 Cl (50 mL) was diluted carefully. The aqueous phase was separated and the organic phase was washed with brine (1X 50 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give 4- ((2-methylpyridin-3-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (4.87 g) as a red oil which was used in the next step without further purification. MS M/z 363 (M + H) + .
Step d: to a solution of 4- ((2-methylpyridin-3-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (4.23g, 11.67mmol) in THF (40 mL) at-20 deg.C was added LDA (2M in THF/Hex, 12.00mL, 24.00mmol) dropwise, warmed to RT and stirred for 2h. The reaction was carefully diluted with brine (50 mL). Separating the aqueous phase and the organic phase with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 1,v/v) to give 7' -oxo-7 ',8' -dihydro-5 ' h-spiro [ piperidine-4, 6' -quinoline ] as a yellow oil]-1-carboxylic acid tert-butyl ester (1.23 g). MS M/z 317 (M + H) + .
Intermediate A21
Step a: to a mixture of t-BuOK (5.92g, 52.76mmol) and 1, 2-dimethoxyethane (50 mL) at-60 deg.C was added dropwise a solution of 2-tosylacetonitrile (5.08g, 26.02mmol) in 1, 2-dimethoxyethane (20 mL). To the system was added dropwise a solution of 2-bromonicotinaldehyde (4.81g, 25.86mmol) in 1, 2-dimethoxyethane (20 mL). After stirring at this temperature for 1h, meOH (50 mL) was added, warmed to RT naturally, stirred for 1h and warmed to 85 deg.C, and stirred for an additional 1h. After cooling to RT, the volatiles were removed by concentration under reduced pressure, diluted with brine (200 mL) and extracted with EA (3X 150 mL). The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give 2- (2-bromopyridin-3-yl) acetonitrile (2.21 g). MS M/z197 (M + H) + .
Step b: to a solution of 2- (2-bromopyridin-3-yl) acetonitrile (2.21g, 11.21mmol) in DMF (20 mL) at 0 deg.C was added sodium hydride (60% dispersion in mineral oil, 1.12g, 28.03mmol) in portions. The reaction was warmed to 60 ℃ and stirred for 1.5h. Tert-butyl bis (2-chloroethyl) carbamate (3.26g, 13.46mmol) was added to the mixture and stirred at 60 ℃ for 2h. After cooling to RT, the reaction was quenched with brine (50 mL) and extracted with EA (3X 100 mL). The combined organic phases were washed with brine (3X 80 mL) and over anhydrous Na 2 SO 4 The mixture is dried and then is dried,filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 3,v/v) to give 4- (2-bromopyridin-3-yl) -4-cyanopiperidine-1-carboxylic acid tert-butyl ester (1.56 g). MS: m/z 366 (M + H) +.
Step c: under nitrogen atmosphere, 4- (2-bromopyridin-3-yl) -4-cyanopiperidine-1-carboxylic acid tert-butyl ester (1.56g, 4.26mmol), K 2 CO 3 (2.35g, 17.04mmol), trimethylcyclotriboroxane (1.07g, 8.52mmol), pd (PPh) 3 ) 4 (47mg, 0.041mmol), a mixture of 1, 4-dioxane (40 mL) and water (8 mL) was stirred at 110 ℃ for 2h. Supplemented with trimethylcyclotriboroxane (2.15g, 17.13mmol) and Pd (PPh) 3 ) 4 (45mg, 0.039mmol) and stirring for a further 3h. After cooling to RT, the reaction was diluted with brine (100 mL), extracted with EA (3X 100 mL), the organic phases combined and washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =2, 1,v/v) to give 4-cyano-4- (2-methylpyridin-3-yl) piperidine-1-carboxylic acid tert-butyl ester (1.08 g). MS M/z 302 (M + H) + .
Step d: to a solution of tert-butyl 4-cyano-4- (2-methylpyridin-3-yl) piperidine-1-carboxylate (1.08g, 3.58mmol) in MeOH (50 mL) at 0 deg.C was added H dropwise 2 SO 4 (98%, 45 mL). The system was stirred at reflux temperature for 18h. After cooling to room temperature, the reaction was poured into an ice/water mixture (200 mL) and the pH was adjusted to 9 with NaOH. To this mixture was added (Boc) 2 O (11.00g, 50.40mmol) and stirred at room temperature for 2h. Extracting with EA (3X 100 mL), combining the organic phases, and purifying with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give 4- (2-methylpyridin-3-yl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester (467 mg). MS: M/z 335 (M + H) + .
Step e: to a 0 ℃ solution of 1-tert-butyl 4-methyl 4- (2-methylpyridin-3-yl) piperidine-1, 4-dicarboxylate (467mg, 1.40mmol) in THF (10.50 mL) was added dropwise potassium bis (trimethylsilyl) amide (1M in THF, 7.00mL, 7.00mmol) under a nitrogen atmosphere. It was allowed to warm to RT and stirred for 3.5h, then quenched with saturated ammonium chloride (10 mL) and extracted with EA (3X 40 mL).The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give 6-oxo-6, 7-dihydrospiro [ cyclopenta [ b ] b]Pyridine-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (170 mg). MS: M/z 303 (M + H) + .
Intermediate A22
A, step a: to a solution of tert-butyl 4-formylpiperidine-1-carboxylate (15.00g, 70.33mmol) in DMF (60 mL) at 0 deg.C was added lithium tert-butoxide (6.75g, 84.44mmol) in portions. The system was stirred at 0 ℃ for 30 minutes. To this mixture was added 3-bromopropene (9.73g, 80.44mmol) dropwise at 0 ℃ and stirred at this temperature for 1h. The reaction was diluted with brine (100 mL) and extracted with EA (3X 200 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 20,v/v) to give 4-allyl-4-formylpiperidine-1-carboxylic acid tert-butyl ester (7.01 g). MS M/z 254 (M + H) + .
Step b: to a solution of tert-butyl 4-allyl-4-formylpiperidine-1-carboxylate (7.01g, 27.63mmol) in THF (30 mL) at-78 deg.C was added dropwise allyl magnesium bromide (1M in THF, 63.55mL, 63.55mmol). Warm to RT and stir for 1.5h. The reaction was quenched with saturated ammonium chloride. Extract with EA (3X 200 mL). The combined organic phases were washed with brine (1X 200 mL) and anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave tert-butyl 4-allyl-4- (1-hydroxyallyl) piperidine-1-carboxylate (7.01 g). MS M/z 282 (M + H) + .
Step c: to a solution of tert-butyl 4-allyl-4- (1-hydroxyallyl) piperidine-1-carboxylate (7.00g, 24.88mmol) in DCM (50 mL) was added portionwise Daisy-Martin's oxidant (12.66g, 29.85mmol). After stirring at RT for 1.5h, the reaction was diluted with brine (150 mL) and extracted with EA (3X 200 mL). The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. Chromatography on silica gel (EA: hex =1) The residue was purified to give tert-butyl 4-acryloyl-4-allylpiperidine-1-carboxylate (5.63 g). MS M/z 280 (M + H) + .
Step d: a mixture of tert-butyl 4-acryloyl-4-allylpiperidine-1-carboxylate (5.63g, 20.15mmol), grubbs II (428mg, 0.50mmol) and toluene (30 mL) was stirred at 85 ℃ for 3.5h under nitrogen. After cooling to RT, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 5,v/v) to give 1-oxo-8-azaspiro [4.5]Tert-butyl dec-2-ene-8-carboxylate (3.61 g). MS M/z 252 (M + H) + .
Step e: sodium hydride (60% dispersion in mineral oil, 730mg, 18.25mmol) was added in portions to a DMSO (50 mL) solution of trimethyl sulfoxide iodide (3.79g, 17.22mmol), and after stirring for 30min, 1-oxo-8-azaspiro [4.5 ] was added dropwise]Decyl-2-ene-8-carboxylic acid tert-butyl ester (DMSO solution, 3.61g, 14.36mmol). The system was stirred at RT for 1.5h. The reaction was diluted with brine (200 mL) and extracted with EA (3X 200 mL). The combined organic phases were washed with brine (3X 200 mL) and anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 2-oxo spiro [ bicyclo [3.1.0 ]]Hexane-3, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (3.60 g). MS M/z 266 (M + H) + .
Intermediate A23
Step a: to a solution of tetrahydro-2H-pyran-4-ol (3.54g, 34.66mmol), triethylamine (4.65g, 45.95mmol) in DCM (100 mL) at-10 deg.C was added MsCl (4.61g, 40.24mmol). After stirring for 30min, the reaction was diluted with water (100 mL) and extracted with DCM (100mL, 50mL). The combined organic phases were washed with brine (1X 50 mL) and anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave tetrahydro-2H-pyran-4-yl methanesulfonate (6.74 g). MS M/z 181 (M + H) + .
Step b: to 1 '-benzyl-6-methoxyspiro [ indene-2, 4' -piperidine]A solution of (1M in DCM, 15.00mL, 15.00mmol) of (1H) -one (4.35g, 13.53mmol) in DCM (200 mL) was added and stirred at 45 ℃ for 13H.Supplement BBr 3 (1M in DCM, 5.00mL, 5.00mmol) and stirred at 45 ℃ for 24h. After cooling to RT, the reaction was diluted with water (150 mL) and NaHCO was added portionwise 3 (20.00 g). The resulting mixture was extracted with DCM (2X 100 mL), the organic phases were combined and washed with anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 1 '-benzyl-6-hydroxy spiro [ indene-2, 4' -piperidine]-1 (3H) -one (2.80 g), used in the next step without further purification. MS: M/z 308 (M + H) + .
Step c: 1 '-benzyl-6-hydroxy spiro [ indene-2, 4' -piperidine]-1 (3H) -one (2.80g, 9.11mmol), tetrahydro-2H-pyran-4-yl methanesulfonate (3.40g, 18.87mmol) and K 2 CO 3 A mixture of (8.23g, 59.55mmol) and DMF (60 mL) was stirred at 110 ℃ for 5.5h. Supplemented with tetrahydro-2H-pyran-4-yl methanesulfonate (1.10g, 6.10mmol) and K 2 CO 3 (4.55g, 32.92mmol) and stirred at 110 ℃ for 1.5h. After cooling to RT, the mixture was diluted with water (300 mL) and EA (600 mL). The aqueous phase was separated and extracted with EA (1X 200 mL), the organic phases combined, washed with water (2X 300 mL) and brine (1X 300 mL), over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) 40,v/v to give 1 '-benzyl-6- ((tetrahydro-2H-pyran-4-yl) oxy) spiro [ indene-2, 4' -piperidine]-1 (3H) -one (1.70 g). MS M/z 392 (M + H) + .
Step d: reacting 1 '-benzyl-6- ((tetrahydro-2H-pyran-4-yl) oxy) spiro [ indene-2, 4' -piperidine in hydrogen atmosphere]-1 (3H) -one (1.70g, 4.34mmol) and Pd (OH) 2 A solution of (10%, 1.21 g) MeOH was stirred at RT for 3h. The reaction system was filtered. To the filtrate was added (Boc) 2 O (1.10g, 5.04mmol) and stirring at room temperature for 40h. The reaction was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 5,v/v) to give 1-oxo-6- ((tetrahydro-2H-pyran-4-yl) oxy) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.45 g). MS M/z 402 (M + H) + .
Intermediate A24
Under nitrogen atmosphere, 6-bromo-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1017mg, 2.67mmol), diethyl phosphonate (564mg, 4.08mmol), potassium phosphate (1156 mg, 5.45mmol), pd (OAc) 2 A mixture of (63mg, 0.28mmol), xantPhos (307mg, 0.53mmol) and DMF (10 mL) was stirred at 130 ℃ for 21h. After cooling to RT, the reaction was quenched with water (60 mL), filtered, and the filter cake rinsed with EA (2X 30 mL). The filtrates were separated and the aqueous layer was extracted with EA (2X 60 mL). The combined organic phases were passed over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue is purified by silica gel chromatography (eluting with EA) to give 6- (diethoxyphosphoryl) -1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (134 mg) 1' -carboxylate, used in the next step without further purification. MS: M/z 438 (M + H) + .
Intermediate A25
Intermediate a25 was synthesized according to the procedure of y.uto et al/bioorg.med.chem.lett.20 (2010) 746-754.
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 11
Intermediate A26
Step a: LDA (2M solution of THF/Hex, 12.00mL, 24.00mmol) was added dropwise to a-65 ℃ solution of 1-tert-butyl 4-ethyl piperidine-1, 4-dicarboxylate (5.23g, 20.32mmol) in THF (30 mL). The resulting mixture was stirred at this temperature for 1.0h. 2-bromobenzaldehyde (3.44g, 18.59mmol) was added dropwise at-70 ℃. After stirring for 1h, the mixture was saltedWater (40 mL) was quenched. Separating the organic phase with anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave 4- ((2-bromophenyl) (hydroxy) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (9.15 g) which was used in the next step without further purification. MS M/z 442 (M + H) + .
Step b: to a solution of 4- ((2-bromophenyl) (hydroxy) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (9.15g, 20.68mmol) in DCM (70 ml) at-5 ℃ was added dess-martin oxidant (18.02g, 42.49mmol). The system was stirred at RT for 2.5h. With Na 2 S 2 O 3 Aqueous (25%, 1X 80 mL), saturated NaHCO3 (1X 80 mL) and brine (1X 100 mL). The organic phase is treated with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 5,v/v) to give 4- (2-bromobenzoyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (7.16 g). MS M/z 440 (M + H) + .
Step c: to a solution of 4- (2-bromobenzoyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (2.00g, 4.54mmol) in THF (20 mL) at-80 deg.C was added 1.8mL of n-butyllithium (2.5M in THF/Hex) with nitrogen blanketing. The system naturally returns to the room temperature, and stirring is continued for 1h. The system was quenched by adding 30mL of saturated brine and the organic phase was collected. The aqueous phase was extracted by addition of 20mL of EA. The organic phases were combined and anhydrous Na 2 SO 4 Drying, filtering, and concentrating under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give 1, 3-dioxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1' -Carboxylic acid tert-butyl ester (500 mg), MS: M/z 316 (M + H) +.
Intermediate A27
Intermediate A27 was synthesized according to the procedure of J.org.chem.1999,64, 5504-5510.
Intermediate A28
Step a: to a solution of ethyl 2-chlorothiazole-4-carboxylate (24.95g, 130.19mmol) at 0 deg.C in MeOH (250 mL) was added NaBH in portions 4 (17.29g, 456.97mmol). The mixture was allowed to warm to RT and stirred for 2h. The reaction was diluted with water (200 mL) and concentrated under reduced pressure to remove volatiles. The system was extracted with EA (2X 200 mL), the combined organic phases were washed with brine (1X 400 mL), anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give (2-chlorothiazol-4-yl) methanol (18.88 g). MS M/z 150 (M + H) + .
Step b: to a solution of (2-chlorothiazol-4-yl) methanol (18.88g, 130.19mmol) and triethylamine (25.56g, 252.57mmol) in DCM (200 mL) was added MsCl (15.96g, 139.30mmol) dropwise and added dropwise over 15min. The system was stirred for 25min at RT. The reaction was quenched with brine (200 mL) and the aqueous phase was separated. Anhydrous Na for organic phase 2 SO 4 Dried, filtered and concentrated under reduced pressure to give (2-chlorothiazol-4-yl) methyl methanesulfonate, which was used in the next step without further purification. MS M/z 228 (M + H) + .
Step c: LDA (2M THF/Hex solution, 75.00mL, 150.00mmol) was added dropwise to a-60 ℃ solution of 1-tert-butyl 4-piperidine-1, 4-dicarboxylate (35.67g, 138.62mmol) in THF (200 mL) under nitrogen for 30min. Then a solution of methanesulfonic acid (2-chlorothiazol-4-yl) methyl ester in THF (50 mL) was added dropwise, warmed to RT naturally and stirred for 2h. The reaction was quenched with brine (300 mL). Separating the organic phase with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give 4- ((2-chlorothiazol-4-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (38.12 g). MS M/z 389 (M + H) + .
Step d: LDA (2M solution in THF/Hex, 11.00mL, 22.00mmol) was added dropwise to a-60 deg.C solution of 4- ((2-chlorothiazol-4-yl) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (8.51g, 21.88mmol) in THF (80 mL) under a nitrogen atmosphere. After the addition was complete, the reaction was quenched with brine (50 mL). Separating the organic phase with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1To 2-chloro-6-oxo-4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (1.93 g). MS: M/z 343 (M + H) + .
Intermediate A29
Step (a-c) Synthesis of 1- (tert-butyloxycarbonyl) -4- (thien-2-ylmethyl) piperidine-4-carboxylic acid with reference to step (b-c) of intermediate A28 and step (b) of intermediate A3.
Step d: a mixture of 1- (tert-butyloxycarbonyl) -4- (thiophen-2-ylmethyl) piperidine-4-carboxylic acid (4.92g, 15.12mmol) and PPA (30.12 g) was stirred at 110 ℃ for 5h. The reaction was poured into an ice/water mixture (100 mL) and the pH adjusted to 10 with NaOH. Then add (Boc) 2 O (5.05g, 23.14mmol) and stirred at room temperature for 18h. Extract with EA (2X 50 mL). The combined organic phases were washed with brine (1X 50 mL) and dried over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 2-tert-butyl-4-oxo-4, 6-dihydrospiro [ cyclopenta [ b ]]Thiophene-5, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (1.70 g). MS: M/z 364 (M + H) + .
Step e: a mixture of 1- (tert-butoxycarbonyl) -4- (thien-2-ylmethyl) piperidine-4-carboxylic acid (4.88g, 15.12mmol), HCl (4M in 1, 4-dioxane, 8 mL), and DCM (50 mL) was stirred at RT for 1h. The reaction was concentrated under reduced pressure. PPA (21.15 g) was added and the system was stirred at 110 ℃ for 1.5h. The reaction was poured into an ice/water mixture (100 mL) and the pH was adjusted to 10 with NaOH. Then add (Boc) 2 O (5.12g, 23.46mmol) and stirred at room temperature for 18h. Extract with EA (2X 50 mL). The combined organic phases were washed with brine (1X 100 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 10,v/v) to give 4-oxo-4, 6-dihydro-4 spiro [ cyclopenta [ b)]Thiophene-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (2.71 g). MS M/z 308 (M + H) + .
Intermediate A30
Step a: to a solution of benzyl alcohol (5.15g, 47.62mmol) in DMF (50 mL) was added sodium hydride (60% dispersion in mineral oil, 3.01g, 75.25mmol) in portions, and the mixture was stirred for 20min. 4-chloropyridine-2-carboxylic acid (2.68g, 17.01mmol) was added and stirred at 85 ℃ for 3.5h. After cooling to RT, HCl (4M in 1, 4-dioxane, 10 mL) was added. The system was used directly in the next step. MS M/z 230 (M + H) + .
Step b: b, mixing the reaction system in the step a with NaHCO 3 (7.51g,89.39mmol),CH 3 I (1.5 mL) was mixed with DMF (10 mL). After stirring for 0.5h, CH is added 3 I (1.5 mL) and stirred for 16h. The reaction was diluted with EA (250 mL), filtered, and the filtrate was washed with brine (2X 150 mL). The organic phase is passed through anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, v/v) to give methyl 4- (benzyloxy) pyridine-2-carboxylate (1.50 g). MS M/z 244 (M + H) + .
Step c: methyl 4- (benzyloxy) pyridine-2-carboxylate (1.50g, 6.17mmol), liBH 4 A mixture of (2M in THF, 9.00mL, 18.00mmol) and THF (40 mL) was stirred at 50 deg.C for 1h. The reaction was diluted with MeOH (15 mL) and water (150 mL) and extracted with EA (200mL, 50mL). The combined organic phases were washed with brine (2X 100 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give (4- (benzyloxy) pyridin-2-yl) methanol (0.50 g). MS M/z 216 (M + H) + .
Step d: a mixture of (4- (benzyloxy) pyridin-2-yl) methanol (0.50g, 2.32mmol), dess-martin oxidant (1.25g, 2.95mmol) and DCM (20 mL) was stirred for 1.5h. The reaction solution is saturated NaHSO 3 Aqueous solution, saturated NaHCO 3 Aqueous and DCM (50 mL). The aqueous phase was separated and extracted with DCM (50 mL). The combined organic phases were washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give 4- (benzyloxy) pyridine-2-carbaldehyde (0.40 g). MS: M/z 214 (M + H) + .
Step e: LDA (2M solution of THF/Hex, 1.30mL, 2.60mmol) was added dropwise to a 0 ℃ solution of piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (0.52g, 2.02mmol) in THF (15 mL). The system was cooled to-70 ℃ and a solution of 4- (benzyloxy) pyridine-2-carbaldehyde (0.40g, 1.88mmol) in THF (5 mL) was added. It was warmed to-15 ℃ and stirred for 30min, then quenched with saturated ammonium chloride (10 mL), diluted with water (50 mL) and extracted with EA (1X 100 mL). The organic phase was washed with brine (2X 50 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex = 1) to give 4- ((4- (benzyloxy) pyridin-2-yl) (hydroxy) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (0.25 g). MS: M/z 471 (M + H) + .
Step f: 4- ((4- (benzyloxy) pyridin-2-yl) (hydroxy) methyl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (0.25g, 0.53mmol), liBH 4 (2M in THF, 1.00mL, 2.00mmol) in THF (10 mL) was stirred at 55 deg.C for 40min. The reaction was quenched with MeOH (10 mL) and concentrated under reduced pressure to remove volatiles. The residue was diluted with water (150 mL) and extracted with EA (1X 50 mL). The organic phase was washed with brine (1X 30 mL) and anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave tert-butyl 4- ((4- (benzyloxy) pyridin-2-yl) (hydroxy) methyl) -4- (hydroxymethyl) piperidine-1-carboxylate (0.22 g). MS: M/z 429 (M + H) + .
Step g: a mixture of tert-butyl 4- ((4- (benzyloxy) pyridin-2-yl) (hydroxy) methyl) -4- (hydroxymethyl) piperidine-1-carboxylate (0.22g, 0.51mmol), pd/C (10%, 0.12 g) and MeOH (20 mL) was stirred under a hydrogen atmosphere for 1.5h. The reaction mixture was filtered, the filter cake was rinsed with MeOH, and the filtrate was concentrated under reduced pressure to give tert-butyl 4- (hydroxy (4-hydroxypyridin-2-yl) methyl) -4- (hydroxymethyl) piperidine-1-carboxylate (154 mg). MS M/z 339 (M + H) + .
Step h: to a solution of tert-butyl 4- (hydroxy (4-hydroxypyridin-2-yl) methyl) -4- (hydroxymethyl) piperidine-1-carboxylate (120mg, 0.36mmol) and triphenylphosphine (175mg, 0.67mmol) in THF (10 mL) was added N, N, N ', N' -tetramethylazodicarboxamide (158mg, 0.68mmol). The mixture was stirred at RT for 30min. Chromatography on silica gel (with MeOH: DCM =)1,7, v/v) to give 1-hydroxy-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine)]-1' -carboxylic acid tert-butyl ester (100 mg). MS M/z 321 (M + H) + .
Step i: 1-hydroxy-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]A mixture of tert-butyl (0.35g, 1.09mmol) -1' -carboxylate, dess-martin oxidant (0.72g, 1.70mmol) and DCM (35 mL) was stirred at RT for 2h. Saturated Na for system 2 SO 3 (1X 20 mL) and saturated NaHCO 3 Aqueous (1X 20 mL) wash. Anhydrous Na for organic phase 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 1, 7-dioxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (0.33 g). MS M/z 319 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 12
Intermediate B1
According to the steps of WO 2017211303A 1, 4-iodoisatin is used as a raw material to synthesize an intermediate B1 through three steps.
Intermediate B2
According to the steps of WO 2017211303A 1, 2-amino-3-bromo-6-chloropyrazine is used as a raw material to synthesize an intermediate B2 through 2 steps.
The following compounds were synthesized using the above procedure and the corresponding starting materials.
Watch 13
Intermediate B3
2-fluoro-3-chloro-4-iodopyridine (10.10 g, 39.23mmol) and DMSO (50 mL) were added to a sealed tube and aqueous ammonia (25%, 50 mL) was added dropwise. The system was stirred at 80 ℃ for 16h. After cooling to RT, the reaction was poured into water (250 mL), filtered to give a precipitate, dissolved in DCM (280 mL), washed with brine (1X 100 mL), and washed with anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure gave 3-chloro-4-iodopyridin-2-amine (7.01 g). MS: M/z 255 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
TABLE 14
Intermediate B4
Under nitrogen atmosphere, 3-chloro-4-iodopyridin-2-amine (25.53g, 100.33mmol), 3-amino-5-chloropyrazine-2-thiol sodium (20.18g, 109.92mmol), pd 2 (dba) 3 A mixture of (4.47g, 4.88mmol), xantPhos (5.81g, 10.04mmol) and DIEA (26.12g, 202.10mmol) in 1, 4-dioxane (100 mL) was stirred at 70 ℃ for 1.5h. After cooling to room temperature, the reaction was filtered through celite, and then washed with 1, 4-dioxane (30 mL) and the filtrate was concentrated under reduced pressure. DCM (100 mL) and EA (100 mL) were added to the residue and stirred for 40min. The precipitate was collected and dried in a vacuum oven to give 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (13.86 g). MS: M/z288 (M + H) + .
The following compounds were synthesized using the above procedure and the corresponding starting materials.
Watch 15
Example 1
(R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -2, 3-dihydrospiro [ indene-1, 4' -piperidine ] -2-amine
Step a: a mixture of compound 1H-indene (11.62g, 0.10mol) and LiHMDS (220mL, 11mol/L in THF) in THF (120 mL) was stirred at-50 ℃ for 1H. Tert-butyl bis (2-chloroethyl) carbamate (24.21g, 0.10mol) was added to the reaction solution and stirred at-50 ℃ for 1h. Quench with brine (300 mL). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give the compound spiro [ indene-1, 4' -piperidine as a yellow solid]-1' -carboxylic acid tert-butyl ester (10.36g, 36%). MS 286 (M + H) + .
Step b: the compound spiro [ indene-1, 4' -piperidine]A solution of tert-butyl (117.02g, 0.41mol) 1' -carboxylate and borane dimethylsulfide complex (10 mol/L,220 mL) in THF (800 mL) was stirred at 0 ℃ for 3h. NaOH (2 mol/L, 1.2L) and H were added 2 O 2 (300 mL) and stirred at 0 ℃ for 1h. Collecting organic phase, and adding anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 2-hydroxy-2, 3-dihydrospiro [ indene-1, 4' -piperidine]-1 '-Carboxylic acid tert-butyl ester and 3-hydroxy-2, 3-dihydrospiro [ indene-1, 4' -piperidine]Tert-butyl-1' -carboxylate, yellow oil (130.33 g, crude). MS:304 (M + H) + .
Step c: 2-hydroxy-2, 3-dihydrospiro [ indene-1, 4' -piperidine]-1 '-Carboxylic acid tert-butyl ester and 3-hydroxy-2, 3-dihydrospiro [ indene-1, 4' -piperidine]A mixture of tert-butyl (130.02g, 0.43mol) -1' -carboxylate, dess-Martin oxidant (364.76g, 0.86mol) and DCM (2L) was stirred at 25 ℃ for 12h. Filtration reactionThe reaction solution was washed with saturated sodium bicarbonate solution (1L) and brine (1L), and dried over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give 3-oxo-2, 3-dihydrospiro [ indene-1, 4' -piperidine as a white solid]Tert-butyl-1' -carboxylate (41.75g, 34%, two-step yield). MS:302 (M + H) + .
Step d: to the compound 3-oxo-2, 3-dihydrospiro [ indene-1, 4' -piperidine]To a solution of tert-butyl (41.01g, 0.14mol) of (E) -1' -carboxylate in ethyl titanate (80 mL) was added R- (+) -tert-butylsulfinamide (49.46g, 0.41mol). The system was stirred at 85 ℃ for 2h. EA (0.5L) and water (0.5L) were added to the reaction system. The reaction was filtered and the organic phase was collected. The aqueous phase was extracted with EA (200 mL. Times.2). The combined organic phases were washed with brine (500 mL) and anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain compound (R, E) -2- ((tert-butylsulfinyl) imino) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (132.05 g, crude). MS:405 (M + H) + The impure sample was used directly in the next step. .
Step e: the compound (R, E) -2- ((tert-butylsulfinyl) imino) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]A solution of tert-butyl (1' -carboxylate) (132.02g, 0.33mol) in THF (200 mL) was cooled to-50 ℃ and stirred. Adding NaBH 4 (7.71g, 0.51mol), the temperature was raised naturally to RT. Quench with saturated ammonium chloride solution (100 mL). Collecting organic phase, and adding anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. Purifying the residue by column chromatography to obtain (R) -2- (((R) -tert-butylsulfinyl) amino) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]Tert-butyl (E) -1' -carboxylate was a white solid (27.25g, 49%, two-step yield). MS:407 (M + H) + .
Step f: (R) -2- (((R) -tert-butylsulfinyl) amino) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.16g, 3.98mmol), CF 3 A solution of COOH (3.6 mL) in DCM (20 mL) was stirred at 25 ℃ for 1.5h. The reaction solution was concentrated under reduced pressure, the residue was dissolved in NMP (15 mL), and 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (1.03g, 3.59mmol) and K were added 2 CO 3 (6.60g, 47.76mmol) and stirred at 90 ℃ for 16h. Into the reaction solutionAddition of H 2 O (30 mL) and filtered. The filter cake was dissolved in DCM (40 mL) and washed with brine (40 mL). Anhydrous Na for organic phase 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain compound (R) -N- ((R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-3-yl) pyrimidin-4-yl) thio) pyrazin-2-yl) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]-2-yl) -2-methylpropane-2-sulfinamide (1.55g, 70%) as a yellow solid.
Step g: to the compound (R) -N- ((R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]To a solution of (2-yl) -2-methylpropane-2-sulfinamide (1.52g, 2.72mmol) in DCM (20 mL) was added HCl/1, 4-dioxane (2mL, 4 mol/L). The system was stirred at 25 ℃ for 1h and the precipitate was collected by filtration. The filter cake was dispersed in DCM (30 mL) and ammonium hydroxide (5 mL) was added to adjust the pH>10. The mixture was washed with brine (40 mL) and anhydrous Na 2 SO 4 Dried and concentrated under reduced pressure. Purifying the residue by column chromatography to obtain the compound (R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -2, 3-dihydrospiro [ indene-1, 4' -piperidine]2-amine as a yellow solid (530mg, 42%). MS:454 (M + H) + .1H NMR(400MHz,DMSO-d6)δ7.64-7.66(m,2H),7.30(d,1H),7.20(d,1H),7.13-7.15(m,2H),6.78(d,1H),4.05-4.09(m,1H),3.91-3.95(m,1H),3.54-3.60(m,3H),3.12-3.18(m,1H),2.57-2.63(m,1H),1.91-2.09(m,2H),1.66-1.76(m,1H),1.49-1.58(m,1H).
Example 2
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -1-amine
Step a: sodium hydride (60%) (3.63g, 90.80mmol) was added to a solution of compound 2, 3-dihydro-1H-inden-1-one (4.00g, 30.27mmol) in DMF (80 mL). The mixture was stirred at 16 ℃ for 30min. Tert-butyl bis (2-chloroethyl) carbamate (8.06g, 33.29mmol) was added dropwise. The mixture was then stirred at 60 ℃ for 16h. The mixture was quenched with brine (200 mL) and extracted with EA (100 mL. Times.2). Will be provided withThe organic phases were combined and washed with brine (100 mL. Times.2) and anhydrous Na 2 SO 4 And (5) drying. After concentration, the residue was purified by column chromatography to give the compound 1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (1.21g, 13%) dark red oil. MS:302 (M + H) + .
Step b: after heating ethyl titanate (12.00 g) to 90 deg.C, the compound 1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (1.21g, 4.01mmol) of (1' -carboxylic acid and (R) -2-methylpropane-2-sulfinamide (1.22g, 12.04mmol) were added. After stirring at 90 ℃ for 19h. The mixture was poured into EA (200 mL) and brine (200 mL) was added. After stirring for 15 minutes, filtration was carried out. The filtrate was partitioned. The organic phase was washed with brine (200 mL. Times.2) over anhydrous Na 2 SO 4 And (5) drying. The solid was filtered off and the filtrate was concentrated under reduced pressure. Purifying the residue by column chromatography to obtain (R, Z) -1- ((tert-butylsulfinyl) imino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (1.01g, 62%) 1' -carboxylate as a black solid. MS:405 (M + H) + .
Step c: reacting (R, Z) -1- ((tert-butylsulfinyl) imino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]A solution of tert-butyl (1.01g, 2.50mmol) of the (E) -1' -carboxylate in THF (10 mL) was cooled to-50 ℃. Adding NaBH in portions 4 (142mg, 3.74mmol). The temperature was allowed to rise to room temperature, stirred for 15.5h, and then poured into EA (100 mL). The mixture was washed with brine (100 mL. Times.3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purifying the residue by column chromatography to obtain the compound (S) -1- (((R) -tert-butylsulfinyl) amino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl-1-carboxylate (580 mg, 57%) as a yellow oil. MS:407 (M + H) + .
Step d: the compound (S) -1- (((R) -tert-butylsulfinyl) amino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]A solution of tert-butyl-1' -carboxylate (580 mg, 1.43mmol) and TFA (1 mL) in DCM (5 mL) was stirred at 20 ℃ for 40min. Concentrating the solution to obtain compound (R) -N- ((S) -1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1-yl) -2-methylpropane-2-sulfinamide (520mg, 90%) as a yellow oil. MS:307 (M + H) + .
Step e: mixing the compound (R) -N- ((S) -1, 3-dihydrospiro [ indene-2, 4' -piperazine)Pyridine (II)]-1-yl) -2-methylpropane-2-sulfinamide (260mg, 0.62mmol), 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (196mg, 0.68mmol), K 2 CO 3 (427mg, 3.09mmol) and NMP (8 mL) were stirred at 100 ℃ for 16h. The mixture was poured into EA (200 mL) and washed with brine (200 mL × 3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purifying the residue by column chromatography to obtain the compound (R) -N- ((S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) inden-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1-yl) -2-methylpropane-2-sulfinamide (260mg, 65%) as a yellow solid. MS:558 (M + H) + .
Step f: the compound (R) -N- ((S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1-yl) -2-methylpropane-2-sulfinamide (260mg, 0.47mmol) was dissolved in DCM (5 mL) and HCl/1, 4-dioxane (4 mol/L,5 mL) was added dropwise. The mixture was stirred at 20 ℃ for 30 minutes. The mixture was concentrated and the residue was dissolved in methanol (2 mL). And EA (5 mL) was added. The solid was collected by filtration to give the compound (S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1-amine (123mg, 54%) as an off-white solid. MS:454 (M + H) + . 1 H NMR(400MHz,DMSO-d6)δ7.81(d,1H),7.72(s,1H),7.62(d,1H),7.27-7.36(m,3H),6.12(d,1H),4.21-4.35(m,3H),2.97-3.24(m,4H),1.77-1.91(m,2H),1.49-1.59(m,2H).
Example 3
(R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine ] -2-amine
Step a: a solution of the compound tert-butyl bis (2-chloroethyl) carbamate (11.00g, 45.43mmol) in HCl/1, 4-dioxane (4 mol/L,200 mL) was stirred at 20 ℃ for 1h. The solution was concentrated and the residue was dissolved in DCE (200 mL). Triethylamine (22.95g, 227.14mmol) and benzaldehyde (7.23g, 68.14mmol) were added. NaBH (OA) is then added in portionsc) 3 (24.07g, 113.57mmol). The mixture was stirred at 20 ℃ for 54h, then EA (300 mL) and brine (200 mL) were added. The organic phase was separated and concentrated under reduced pressure. The residue was dissolved in HCl solution (2 mol/L,200 mL) and washed with EA (100 mL). With saturated Na 2 CO 3 The solution adjusted the pH of the aqueous phase to 9. The mixture was extracted with EA (200 mL). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the compound N-benzyl-2-chloro-N- (2-chloroethyl) ethane-1-amine (8.52g, 81%) as a colorless oil.
Step b: to a mixed solution of the compound N-benzyl-2-chloro-N- (2-chloroethyl) ethan-1-amine (8.52g, 36.70mmol) and 3, 4-dihydronaphthalen-2 (1H) -one (4.88g, 33.36mmol) in THF (80 mL) and DMSO (50 mL) was added potassium t-butoxide (9.36g, 83.14mmol). Stirring was carried out at 20 ℃ for 20h. The mixture was concentrated and diluted with EA (200 mL). Then washed with brine (200 mL. Times.3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give 1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine as a black oil]2-keto (2.32g, 21%). MS 306 (M + H) + .
Step c: adding the compound 1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine to ethyl titanate]-2-ketone (2.32g, 7.60mmol) and (R) -2-methylpropane-2-sulfinamide (2.76g, 22.79mmol). Stirring was carried out at 100 ℃ for 19h. EA (200 mL) and water (200 mL) were added. After filtration, the filtrate was separated into layers and the organic phase was collected. The organic phase was washed with brine (100 mL × 5), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purifying the residue by column chromatography to obtain the compound (R, E) -N- (1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]-2-ylidene) -2-methylpropane-2-sulfinamide (660mg, 21%) as a yellow oil. MS:409 (M + H) + .
Step d: the compound (R, E) -N- (1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]A solution of-2-ylidene) -2-methylpropane-2-sulfinamide (660mg, 1.62mmol) in THF (10 mL) was cooled to-50 ℃. Then add NaBH in portions 4 (122mg, 3.23mmol). The mixture was stirred for 18h and allowed to warm to RT. Quenched with water (50 mL) and extracted with EA (50 mL. Times.2). The organic phases were combined and washed with brine (50 mL. Times.2), dried over anhydrous Na2SO4, filtered and reduced pressureAnd (5) concentrating. Purifying the residue by column chromatography to obtain the compound (R) -N- ((R) -1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]-2-yl) -2-methylpropane-2-sulfinamide (195mg, 29%) as a yellow oil. MS:411 (M + H) + .
Step e: to the compound (R) -N- ((R) -1 '-benzyl-3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]To a solution of (2-yl) -2-methylpropane-2-sulfinamide (195mg, 0.47mmol) in methanol (5 mL) was added palladium hydroxide (20%, 120 mg). Stirred under hydrogen at 40 ℃ for 18h. Filtering and concentrating under reduced pressure to obtain compound (R) -N- ((R) -3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]-2-yl) -2-methylpropane-2-sulfinamide (92mg, 60%). MS:321 (M + H) + .
Step f: the compound (R) -N- ((R) -3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine)]-2-yl) -2-methylpropane-2-sulfinamide (92mg, 0.29mmol) was dissolved in NMP (3 mL). 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (91mg, 0.32mmol) and K were added 2 CO 3 (198mg, 1.44mmol). Stir at 100 ℃ for 3h, dilute with EA (30 mL), and wash with brine (30 mL × 3). Anhydrous Na for organic phase 2 SO 4 And (5) drying. The residue was purified by Pre-TLC to give (R) -N- ((R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine]-2-yl) -2-methylpropane-2-sulfinamide (18mg, 11%) as an off-white solid.
Step g: to the compound (R) -N- ((R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3, 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine]To a solution of (2-yl) -2-methylpropane-2-sulfinamide (18mg, 0.03mmol) in 1, 4-dioxane (2 mL) was added HCl/1, 4-dioxane (4 mol/L,2 mL). After stirring for 30min, concentrate and wash twice with EA. Drying the solid in high vacuum to obtain the compound (R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) 4-dihydro-2H-spiro [ naphthalene-1, 4' -piperidine]-2-amine (14mg, 88%) as an off-white solid. MS:468 (M + H) + .
Example 4
(R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 6-dihydrospiro [ cyclopenta [ b ] pyridine-7, 4' -piperidine ] -6-amine
Step a: naHMDS (38ml, 2mol/L in THF) was added to a solution of the compounds 2-fluoro-3-methylpyridine (5.56g, 50.00mmol) and piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 14.15g, 55.00mmol) in toluene (50 mL) at 0 deg.C, and the mixture was allowed to warm to 20 deg.C and stirred for 24h. The reaction was quenched with brine (100 mL). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give compound 4- (3-methylpyridin-2-yl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (6.32g, 36%) as a yellow oil. MS:349 (M + H) + .
Step b: a solution of compound 4- (3-methylpyridin-2-yl) piperidine-1, 4-dicarboxylic acid 1-tert-butyl 4-ethyl ester (4.80g, 13.78mmol) and LDA (2 mol/L,17 mL) in THF (48 mL) was stirred at 0 ℃ for 0.5h. The volatiles were removed by concentration under reduced pressure. The residue was purified by column chromatography to give 6-oxo-5, 6-dihydrospiro [ cyclopenta [ b ] as a red oil]Pyridine-7, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (0.95g, 23%). MS 303 (M + H) + .
Step c: to 6-oxo-5, 6-dihydrospiro [ cyclopenta [ b ]]Pyridine-7, 4' -piperidines]To a solution of tert-butyl (1' -carboxylate) (0.94g, 3.11mol) in ethyl titanate (5 mL) was added (R) -2-methylpropane-2-sulfinamide (1.13g, 9.33mmol). Stirring was carried out at 80 ℃ for 1h. EA (30 mL) and water (20 mL) were added to the reaction. Filtering, and collecting an organic phase in the filtrate. The aqueous phase was extracted with EA (10 mL. Times.2). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give (R, Z) -6- ((tert-butylsulfinyl) imino) -5, 6-dihydrospiro [ cyclopenta [ b ]]Pyridine-7, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (2.51 g, crude). The reaction was directly put to the next step without further purification. MS:406 (M + H) + .
Step d: the compound (R, Z) -6- ((tert-butylsulfinyl) imino) -5, 6-dihydrospiro [ cyclopenta [ b ]]Pyridine-7, 4' -piperidines]A solution of tert-butyl (2.12 g, crude) 1' -carboxylate in THF (20 mL) was stirred at-50 ℃. Reacting NaBH 4 (176mg, 4.66mmol) was added to the reaction and the temperature was naturally raised to RT. The reaction was quenched with saturated ammonium chloride solution (30 mL). The organic phase was collected, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give (R) -6- (((S) -tert-butylsulfinyl) amino) -5, 6-dihydrospiro [ cyclopenta [ b ] as a yellow solid]Pyridine-7, 4' -piperidines]Tert-butyl (0.21g, 17%, two-step yield) 1' -carboxylate. MS:408 (M + H) + .
Step e: the compound (R) -6- (((S) -tert-butylsulfinyl) amino) -5, 6-dihydrospiro [ cyclopenta [ b ]]Pyridine-7, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (204mg, 0.50mmol) and CF 3 A mixture of COOH (1 mL) in DCM (10 mL) was stirred at 25 ℃ for 1.5h. The reaction was concentrated under reduced pressure. The residue was dissolved in NMP (10 mL) and 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (144mg, 0.50mmol) and K were added 2 CO 3 (0.82g, 6.00mmol), stirred at 95 ℃ for 16h. Addition of H 2 O (50 mL), extracted with EA (30 mL. Times.2). The combined organic phases were washed with brine (50 mL) and dried over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain the compound (S) -N- ((R) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 6-dihydrospiro [ cyclopenta [ b ] b]Pyridine-7, 4' -piperidines]-6-yl) -2-methylpropane-2-sulfinamide (302 mg, crude). The next step was carried out without further purification. MS:559 (M + H) + .
Step f: to the compound (S) -N- ((R) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) pyridine-7, 4' -piperidine]To a solution of (6-yl) -2-methylpropane-2-sulfinamide (302mg, 0.54mmol) in DCM (10 mL) was added HCl/1,4-dixoane (4 mol/L,1 mL). The system was stirred at 25 ℃ for 1h and filtered. The filter cake was dissolved in MeOH (2 mL), DCM (15 mL) was added, stirred for 0.5h and filtered to give the compound (R) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 6-dihydrospiro [ cyclopenta [ b ] as a yellow solid]Pyridine-7, 4' -piperidines]-6-amine (163mg, 71%, two-step yield). MS:455 (M + H) + .1H NMR(600MHz,MeOH-d4)δ8.69(d,1H),8.54(d,1H),7.92-7.96(m,1H),7.88(s,1H),7.75(d,1H),6.58(d,1H),4.54-4.67(m,3H),3.89-3.95(m,1H),3.37-3.61(m,3H),2.79-2.86(m,1H),1.93-2.20(m,3H).
Example 5
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -1-amine
Step a: mixing 6-methoxy-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (557mg, 1.68mmol) and (R) -2-methylpropane-2-sulfinamide (610mg, 5.04mmol) in Ti (OEt) 4 The solution (5 mL) was stirred at 100 ℃ for 16h. After cooling to RT, the reaction was diluted with EA (20 mL) and water (30 mL). Filter through a pad of celite and rinse with EA. The filtrate was washed with brine (1X 50 mL) and dried over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain (R, Z) -1- ((tert-butylsulfinyl) imino) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (0.98 g) -1' -carboxylate, which was used in the next step without further purification. MS M/z 435 (M + H) + .
Step b: to (R, Z) -1- ((tert-butylsulfinyl) imino) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine](ii) -1' -Carboxylic acid tert-butyl ester (0.98g, 2.25mmol) in THF (10 mL) NaBH was added 4 (0.17g, 4.51mmol). The mixture was warmed to RT and stirred for 24h. The reaction was diluted with EA (50 mL) and water (50 mL), the organic phase was separated, washed with brine (1X 50 mL), anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, 5,v/v) to give (S) -1- (((R) -tert-butylsulfinyl) amino) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1' -carboxylic acid tert-butyl ester (380 mg). MS: M/z 437 (M + H) + .
Step c: to (S) -1- (((R) -tert-butylsulfinyl) amino) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (E) -1' -carboxylate (380mg, 0.87mmol) in DCM (10 mL) was added TFA (2 mL) and the mixture was stirred at RT for 1.5h. The system was concentrated under reduced pressure. The residue was dissolved in NMP (10 mL), 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (301mg, 1.04mmol) andK 2 CO 3 (601mg, 4.35mmol). The system was stirred at 100 ℃ for 16h. After cooling to RT, the reaction was diluted with water (50 mL) and EA (50 mL). The aqueous phase was separated and the organic phase was washed with brine (2X 50 mL) and dried over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 120,v/v) to give (R) -N- ((S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-3-yl) -2-methylpropane-2-sulfinamide (254 mg). MS: M/z 588 (M + H) + .
Step d: to (R) -N- ((S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of (3-yl) -2-methylpropane-2-sulfinamide (254mg, 0.43mmol) in 1, 4-dioxane (3 mL) was added HCl (4M in 1, 4-dioxane, 3 mL) dropwise and stirred at RT for 30min. Filtering and drying the collected precipitate in a vacuum oven to obtain (S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1-amine (221 mg, hydrochloride salt). MS: M/z 484 (M + H) + . 1 H NMR(600MHz,MeOH-d4)δ7.90(s,1H),7.76(d,1H),7.28(d,1H),7.12(d,1H),6.95-6.89(m,1H),6.58(d,1H),4.35-4.50(m,3H),3.82(s,3H),3.40-3.49(m,2H),3.08-3.16(m,2H),1.66-2.01(m,4H).
The following examples were synthesized with the corresponding intermediate a and intermediate B, according to the methods described above.
The following examples are in the form of the free base or a pharmaceutically acceptable salt thereof.
Example 82
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 7-dihydrospiro [ cyclopenta [ b ] pyridine-6, 4' -piperidine ] -7-amine
Step a: reacting 7-oxo-5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]A solution of tert-butyl (936mg, 3.10mmol) of-1' -carboxylate and (R) -2-methylpropane-2-sulfinamide (1045mg, 8.62mmol) in ethyl titanate (8 mL) was stirred at 100 ℃ for 2h. After cooling to RT, the reaction was diluted with EA (50 mL) and water (50 mL). Filter through a pad of celite and rinse the filter cake with EA. Separating organic phase from filtrate, and adding anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain (R, Z) -7- ((tert-butylsulfinyl) imino) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (1.41 g). MS: M/z 406 (M + H) + .
Step b: to-40 deg.C of (R, Z) -7- ((tert-butylsulfinyl) imino) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]To a solution of tert-butyl (1.41g, 3.48mmol) of (E) -1' -carboxylate in THF (50 mL) was added BH 3 (1M in THF, 10.00mL, 10.00mmol). The mixture was warmed to RT and stirred for 1h. The reaction was quenched with brine (100 mL). The organic phases were collected, the aqueous phase was extracted with EA (1X 60 mL), the organic phases were combined and dried over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was dissolved in MeOH (100 mL) and stirred at 80 ℃ for 15h. After cooling to RT, the reaction was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) 60, v/v) to give (S) -7- (((R) -tert-butylsulfinyl) amino) -5, 7-dihydrospiro [ cyclopenta [ b)]Pyridine-6, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (309 mg). MS: M/z 408 (M + H) + .
Step c: to (S) -7- (((R) -tert-butylsulfinyl) amino) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines](iii) -1' -Carboxylic acid tert-butyl ester (309mg, 0.76mmol) in DCM (20 mL) HCl (4M in E) was addedSolution A, 2mL, 8.00mmol), stirred at RT for 1.5h. Concentrating under reduced pressure to obtain (S) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-7-amine (227 mg). MS: M/z 204 (M + H) + .
Step d: reacting (S) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]-7-amine (HCl salt, 227mg, 0.73mmol), 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (249mg, 0.86mmol), K 2 CO 3 A mixture of (1149mg, 8.31mmol) and acetonitrile (15 mL) was stirred at reflux for 44h. After cooling to RT, the reaction was diluted with brine (100 mL) and extracted with EA (2X 50 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) to give (S) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) pyrimidin-5-yl) thio) pyrazin-2-yl) -5, 7-dihydrospiro [ cyclopenta [ b)]Pyridine-6, 4' -piperidines]-7-amine (77 mg). MS M/z 455 (M + H) + . 1 H NMR(400MHz,MeOH-d4)δ8.51(s,1H),7.81(d,1H),7.63(s,1H),7.38(s,1H),5.94(d,1H),4.49-4.30(m,3H),3.37-3.09(m,4H),2.05-1.95(m,1H),1.85-1.70(m,2H),1.60-1.50(m,1H).
The following examples were synthesized with the corresponding intermediate a and intermediate B, according to the methods described above.
In step a of example 82, tert-butylsulfinamide was used instead of (R) -2-methylpropane-2-sulfinamide to give the corresponding racemic product.
The following examples are in the form of the free base or a pharmaceutically acceptable salt thereof.
Example 133
(S) -4- ((5- (1-amino-1, 3-dihydrospiro [ indene-2, 4 '-piperidin ] -1' -yl) pyrazin-2-yl) thio) -3-chloropyridin-2-ol
Steps a-c (R) -N- ((S) -1'- (5- ((3-chloro-2-methoxypyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine) was obtained by the step (a-c) of example 5]-1-yl) -2-methylpropane-2-sulfinamide MS M/z 558 (M + H) + .
Step d: mixing (R) -N- ((S) -1' - (5- ((3-chloro-2-methoxypyridin-4-yl) thio) pyridineOxazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]A mixture of-1-yl) -2-methylpropane-2-sulfinamide (112mg, 0.20mmol), DCM (5 mL) and HCl (4M in 1, 4-dioxane, 10 mL) was stirred at RT for 17h. The mixture was concentrated under reduced pressure, the residue was dissolved in MeOH (10 mL), and stirred at 60 ℃ for an additional 23h. After cooling to RT, the reaction was concentrated under reduced pressure. The residue was dispersed in MeOH (2 mL) and EA (20 mL), and the precipitate was collected by filtration and dried under reduced pressure to give (S) -4- ((5- (1-amino-1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1' -yl) pyrazin-2-yl) thio) -3-chloropyridin-2-ol (73 mg). MS M/z 440 (M + H) + . 1 H NMR(400MHz,DMSO-d6)δ8.51(s,1H),8.34(s,1H),7.59(d,1H),7.28-7.37(m,3H),7.23(d,1H),5.52(d,1H),4.28-4.40(m,3H),3.21-3.38(m,3H),3.02-2.99(d,1H),1.75-1.82(m,2H),1.52-1.60(m,2H).
The following examples were synthesized by the above-described method using the corresponding starting materials. .
The following examples are in the form of their free bases or pharmaceutically acceptable salts.
Watch 18
Example 137
(S) -1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -6-ol
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -6-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of (1-amine) (74mg, 0.14mmol) in DCM (2 mL) was added BBr 3 (1M in DCM, 0.71 mL). The system was stirred at RT for 6h. Concentrating under reduced pressure to remove volatiles, dispersing the residue in water,the solid was filtered off and washed with saturated NaHCO 3 The aqueous solution adjusted the pH of the filtrate to 7. The resulting precipitate was collected by filtration and dried in a vacuum oven to give (S) -1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-6-ol (7 mg). And (2) MS: m/z 470 (M + H) + .
The following examples were synthesized by the above-described method using the corresponding starting materials.
Watch 19
Example 139
1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5-methyl-5, 7-dihydrospiro [ cyclopenta [ b ] pyridine-6, 4' -piperidine ] -5-amine
Step a: synthesis of (R, Z) -5- ((tert-butylsulfinyl) imino) -5, 7-dihydrospiro [ cyclopenta [ b ] with reference to step a of example 5]Pyridine-6, 4' -piperidines]-1' -carboxylic acid tert-butyl ester. And (2) MS: m/z 406 (M + H) + .
Step b: to-60 deg.C of (R, Z) -5- ((tert-butylsulfinyl) imino) -5, 7-dihydrospiro [ cyclopenta [ b ]]Pyridine-6, 4' -piperidines]Methyllithium (1.3M in diethyl ether, 14mL, 18.20mmol) was added dropwise to a solution of tert-butyl (1.49g, 3.67mmol) 1' -carboxylate in THF (15 mL). The mixture was warmed to RT and stirred for 20h. Dilute with water (10 mL) and EA (20 mL). The aqueous phase was separated and NaOH (1.00g, 25.00mmol) and (Boc) were added 2 O (0.50 mL). The mixture was stirred at RT for 1.5h. Extraction with EA (2X 50 mL), combining the organic phases, washing with brine (1X 30 mL), over anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1:1, v/v) to give 5- (((R) -tert-butylsulfinyl) amino) -5-methyl-5, 7-dihydrospiro [ cyclopenta [ b ] b)]Pyridine-6, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (82)3mg)。MS:m/z 422(M+H) + .
Step (c-d) Synthesis of 1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5-methyl-5, 7-dihydrospiro [ cyclopenta [ b ] with reference to step (c-d) of example 5]Pyridine-6, 4' -piperidines]5-amine (71 mg). MS: M/z 469 (M + H) + . 1 H NMR(400MHz,MeOH-d4)δ8.50-8.44(m,1H),7.93-7.87(m,1H),7.67-7.61(m,2H),7.41-7.35(m,1H),5.97(d,1H),4.54(m,2H),3.35(d,1H),3.23-3.08(m,3H),1.92-1.78(m,2H),1.57-1.48(m,2H),1.44(s,3H).
Example 140
1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3H-spiro [ indolizine-2, 4' -piperidine ] -7 (1H) -one
Step a: to-10 ℃ 1-hydroxy-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]To a solution of tert-butyl (100mg, 0.31mmol) of (E) -1' -carboxylate and triethylamine (157mg, 1.55mmol) in THF (10 mL) and DCM (2 mL) was added MsCl (66mg, 0.58mmol). The resulting solution was stirred at RT for 1h. The reaction was diluted with water (50 mL) and extracted with DCM (3X 50 mL). The combined organic phases are passed over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to give 1- ((methylsulfonyl) oxy) -7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (155 mg). MS: M/z 399 (M + H) + .
Step b: mixing 1- ((methylsulfonyl) oxy) -7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]A mixture of tert-butyl (155mg, 0.39mmol) 1' -carboxylate, sodium azide (136mg, 2.09mmol) and DMF (5 mL) was stirred at 75 deg.C for 1h and at 85 deg.C for 4h. After cooling to RT, the reaction was diluted with EA (30 mL), filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM =1, 10,v/v) to give the 1-azido-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine)]-1' -carboxylic acid tert-butyl ester (32 mg). MS M/z 346 (M + H) + .
Step c: reacting 1-azido-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]A solution of tert-butyl (32mg, 0.093mmol) 1' -carboxylate, pd/C (10%, 15 mg) in EtOH (6 mL) was stirred under hydrogen for 3h. Filtering the reaction system, leaching the filter cake with EtOH, and concentrating the filtrate under reduced pressure to obtain 1-amino-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]-1' -carboxylic acid tert-butyl ester (26 mg). MS M/z 320 (M + H) + .
Step d: to 1-amino-7-oxo-1, 7-dihydro-3H-spiro [ indolizine-2, 4' -piperidine]To a solution of tert-butyl (26mg, 0.081mmol) of (E) -1' -carboxylate in DCM (2 mL) was added TFA (2 mL) and stirred at room temperature for 30min. The system was concentrated under reduced pressure. The residue was dissolved in NMP (2.5 mL) and 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (46mg, 0.16mmol) and K were added 2 CO 3 (395mg, 2.86mmol), and stirred at 95 ℃ for 16h. After cooling to RT, it was diluted with DCM (30 mL), filtered and concentrated under reduced pressure. The residue was purified by Pre-TLC (MeOH: DCM =1, 3,v/v elution) to give 1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3H-spiro [ indolizine-2, 4' -piperidine]-7 (1H) -one (2 mg). MS: M/z 471 (M + H) + .
The following examples were synthesized by the above-described method using the corresponding starting materials.
Watch 20
Example 142
3- ((2-amino-3-chloropyridin-4-yl) thio) -6- (1-imino-1, 3-dihydrospiro [ indene-2, 4 '-piperidin ] -1' -yl) pyrazin-2-amine
Step a Synthesis of (R, Z) -1- ((tert-butylsulfinyl) imino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine by step a of example 5]1' -Carboxylic acid tert-butyl ester MS M/z 405 (M + H) + .
Step b: to (R, Z) -1- ((tert-butylsulfinyl) imino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (40)5mg, 1.00mmol) in DCM (10 mL) was added TFA (1 mL) and stirred at RT for 1.5h. The system was concentrated under reduced pressure. The residue was dissolved in NMP (10 mL), and 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (288mg, 1.00mmol) and K were added 2 CO 3 (1.38g, 10.00mmol). The system was stirred at 100 ℃ for 18h. After cooling to RT, it was diluted with water (50 mL) and extracted with EA (3X 30 mL). The combined organic phases were washed with brine (1X 100 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH: DCM = 1) 5,v/v to give 3- ((2-amino-3-chloropyridin-4-yl) thio) -6- (1-imino-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -yl) pyrazin-2-amine (50 mg). MS M/z 452 (M + H) + . 1 H NMR(400MHz,MeOH-d4)δ7.83(d,1H),7.37-7.74(m,5H),5.96(d,1H),4.43-4.58(m,2H),3.12-3.28(m,4H),2.01-2.06(m,2H),1.56-1.60(m,2H).
The following examples were synthesized with the corresponding starting materials in accordance with the above procedure.
TABLE 21
Example 148
1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -7-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -1-amine
A, step a: to 7-methoxy-1-oxo-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (552mg, 1.07mmol) of (E) -1' -carboxylate in MeOH (10 mL) were added hydroxylamine hydrochloride (348mg, 5.01mmol) and AcONa (822mg, 10.02mmol). The system was stirred at RT for 4h. The reaction was concentrated under reduced pressure. The residue was dissolved in EA (15 mL) and water (15 mL), the organic phase was separated, washed with brine (1X 15 mL), and dried over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to give (Z) -1- (hydroxyimino) -7-methoxy-1, 3-dihydrospiro [ indene-2 as a yellow solid,4' -piperidines]-1' -carboxylic acid tert-butyl ester (520 mg). MS: M/z 347 (M + H) + .
Step b: mixing (Z) -1- (hydroxyimino) -7-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1' -Carboxylic acid tert-butyl ester (510mg, 1.47mmol), ptO 2 A mixture of (30 mg) and AcOH (10 mL) was stirred under hydrogen at 60 ℃ for 17h. After cooling to RT, the reaction was diluted with EA (45 mL) and water (45 mL), the aqueous phase was separated and washed with K 2 CO 3 The solid adjusted the pH to 10. The system was extracted with DCM (2X 30 mL), and the combined organic phases were washed with brine (1X 50 mL) and anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain 1-amino-7-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine as colorless oil]-1' -carboxylic acid tert-butyl ester (202 mg). MS M/z 333 (M + H) + .
Step c: to 1-amino-7-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine]To a solution of tert-butyl (1' -carboxylate) (199mg, 0.60mmol) in DCM (10 mL) was added TFA (1 mL) and stirred at RT for 1.5h. The system was concentrated under reduced pressure. The residue was dissolved in NMP (5 mL) and 3- ((2-amino-3-chloropyridin-4-yl) thio) -6-chloropyrazin-2-amine (144mg, 0.50mmol) and K were added 2 CO 3 (691mg, 5.90mmol). The system was stirred at 95 ℃ for 3h. After cooling to RT, the reaction was diluted with water (50 mL) and extracted with EA (1X 50 mL). The organic phase was washed with brine (1X 50 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by Pre-TLC (eluting with MeOH: DCM =1, 5,v/v) to give 1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -7-methoxy-1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1-amine (20 mg). MS M/z 484 (M + H) + . 1 H NMR(400MHz,DMSO-d6)δ7.66(s,1H),7.64(d,1H),7.36-7.28(m,1H),6.90(d,1H),6.88(d,1H),5.75(d,1H),4.29(s,1H),4.20(d,1H),4.09(d,1H),3.83(s,3H),3.30-3.15(m,2H),3.10(d,1H),2.96(d,1H),1.87-1.76(m,1H),1.70-1.54(m,2H),1.41(d,1H).
The following examples were synthesized with the corresponding starting materials in accordance with the above procedure.
TABLE 22
Example 150
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -2-methoxy-4, 6-dihydrospiro [ cyclopenta [ d ] thiazole-5, 4' -piperidine ] -4-amine
Step (a-b): synthesis of (S) -4- (((R) -tert-butylsulfinyl) amino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ] with reference to procedure (a-b) of example 5]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester. MS: m/z 448 (M + H) + .
Step c: (S) -4- (((R) -tert-butylsulfinyl) amino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]A mixture of tert-butyl (403mg, 0.90mmol) 1' -carboxylate, naOH (358mg, 8.95mmol) and MeOH (15 mL) was stirred at 65 ℃ for 5h. After cooling to RT, the volatiles were removed by concentration under reduced pressure. The residue was dissolved in water and the pH adjusted to 7 by addition of saturated aqueous citric acid. The system was extracted with EA (3X 30 mL) and the combined organic phases were passed over anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to give (S) -4- (((R) -tert-butylsulfinyl) amino) -2-methoxy-4, 6-dihydrospiro [ cyclopenta [ d ] as a brown oil]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (360 mg). MS: M/z 444 (M + H) + .
Step (d-e) Synthesis of (S) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -2-methoxy-4, 6-dihydrospiro [ cyclopenta [ d ] d) with reference to step (c-d) of example 5]Thiazole-5, 4' -piperidines]-4-amine. MS M/z 491 (M + H) + .
Example 151
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4, 6-dihydrospiro [ cyclopenta [ d ] thiazol-5-, 4' -piperidin ] -4-amine
Step (a-b) Synthesis of (S) -4- (((R) -tert-butylsulfinyl) amino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ] with reference to step (a-b) of example 5]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester. MS M/z 448 (M + H) + .
Step c (S) -4- (((R) -tert-butylsulfinyl) amino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]A mixture of tert-butyl-1' -carboxylate (2.50g, 5.58mmol), TEA (2 mL), pd/C (10%, 690 mg) and MeOH (50 mL) was stirred under hydrogen at 40 ℃ for 24h. Filtration was carried out and Pd/C (10%, 1.32 g) was added to the filtrate. Stirring for another 16h at 50 ℃ under hydrogen atmosphere. Filtering, and concentrating the filtrate under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA: hex =1, v/v) to give (S) -4- (((R) -tert-butylsulfinyl) amino) -4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester (1.28 g). MS M/z 414 (M + H) + .
Step (d-e) Synthesis of (S) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4, 6-dihydrospiro [ cyclopenta [ d ] d) with reference to step (c-d) of example 5]Thiazole-5, 4' -piperidines]-4-amine. MS: M/z 461 (M + H) + . 1 H NMR(400MHz,DMSO-d6)δ8.94(s,1H),7.63-7.66(m,2H),5.76(d,1H),3.99-4.07(m,2H),3.87(s,1H),3.28-3.38(m,2H),2.78-2.93(m,2H),1.47-1.87(m,4H).
In step a of example 5, tert-butylsulfinamide was used instead of (R) -2-methylpropane-2-sulfinamide to give the corresponding racemic product.
The following examples were synthesized with the corresponding starting materials in accordance with the above procedure.
TABLE 23
EXAMPLE 155
(S) -1'- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4, 6-dihydrospiro [ cyclopenta [ d ] thiazole-5, 4' -piperidine ] -6-amine
Step a Synthesis of (R, Z) -6- ((tert-butylsulfinyl) imino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ] with reference to step a of example 5]Thiazole-5, 4' -piperidines]-1' -carboxylic acid tert-butyl ester. MS M/z 446 (M + H) + .
Step b: to (R, Z) -6- ((tert-butylsulfinyl) imino) -2-chloro-4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines](ii) A solution of tert-butyl (4.25g, 9.53mmol) of (1) -carboxylate in THF (30 mL) was added BH 3 (1M in THF, 30.00mL, 30.00mmol). The mixture was warmed to RT and stirred for 18h. The reaction was quenched with brine (50 mL). The organic phase was separated off and washed with anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting with (EA: hex =1, 2,v/v), to give (S) -6- (((R) -tert-butylsulfinyl) amino) -4, 6-dihydrospiro [ cyclopenta [ d ]]Thiazole-5, 4' -piperidines]-1' -Carboxylic acid tert-butyl ester (1.12 g). MS M/z 414 (M + H) + .
Step (c-d) Synthesis of (S) -1' - (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4, 6-dihydrospiro [ cyclopenta [ d ] d with reference to step (c-d) of example 5]Thiazole-5, 4' -piperidines]-6-amine. 1 H NMR(400MHz,DMSO-d6)δ9.01(s,1H),7.63-7.66(m,2H)5.76(d,1H),4.19-4.23(m,2H),4.09(s,1H),3.15-3.32(m,2H),2.80-2.93(m,2H),1.60-1.87(m,4H).MS:m/z 461(M+H) + .
The following examples were synthesized with the corresponding starting materials with reference to the above-described methods.
Watch 24
Example 157
(S) -1'- (6-amino-5- ((3-fluoro-1H-indol-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -1-amine
(S) -1- (4- ((3-amino-5- (1-amino-1, 3-dihydrospiro [ indene-2, 4' -piperidine)]-1' -yl) pyrazin-2-yl) thio) -3, 3-difluoroindolin-1-yl) ethan-1-one (86mg, 0.16mmol) was dissolved in MeOH (8 mL) and NaOH (17mg, 0.43mmol) was added. The system was stirred for a further 21h at 65 ℃. After cooling to RT, the reaction was concentrated under reduced pressure. The residue was diluted with water (10 mL) and EA (20 mL). The separated organic phase was washed with brine (10 mL) and anhydrous Na 2 SO 4 Dried, filtered and concentrated under reduced pressure. Adding EA (5 mL) and Hex (3 mL) for pulping, filtering to collect precipitate, and drying under reduced pressure to obtain (S) -1'- (6-amino-5- ((3-fluoro-1H-indol-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]-1-amine (14 mg). 1 H NMR(400MHz,DMSO-d6)δ7.59(s,1H),7.37-7.21(m,5H),7.13(d,1H),7.00-6.93(m,1H),6.40(d,1H),4.18(d,2H),3.97(s,1H),3.09(m,3H),2.72(m,1H),1.77-1.62(m,2H),1.50-1.47(m,1H),1.20-1.16(m,1H)MS:461(M+H) + .
Example 158
(S) -1- (1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine ] -6-yl) ethan-1-one
Synthesis of (S) -1- (((R) -tert-butylsulfinyl) amino) -6-cyano-1, 3-dihydrospiro [ indene-2, 4' -piperidine) with reference to step (a-b) of example 5]-1' -carboxylic acid tert-butyl ester. MS M/z 432 (M + H) + .
Step c: to-50 deg.C (S) -1- (((R) -tert-butylsulfinyl) amino) -6-cyano-1, 3-dihydrospiro [ indene-2, 4' -piperidine]Methyl magnesium bromide (3M solution in THF/Hex, 0.50mL, 1.50mmol) was added dropwise to a solution of tert-butyl (430mg, 1.00mmol) 1' -carboxylate in THF (10 mL). Naturally warming to room temperature and stirring for 24h. The reaction was quenched with brine (10 mL). Separating the organic phase with anhydrous Na 2 SO 4 Drying, filtering and concentrating under reduced pressure to obtain (S) -6-acetyl-1- (((R) -tert-butylsulfinyl) amino) -1, 3-dihydrospiro [ indene-2, 4' -piperidine]Tert-butyl (0.72 g) 1' -carboxylate, which was used in the next step without further purification. MS M/z 449 (M + H)) + .
Synthesis of (S) -1- (1-amino-1 '- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -1, 3-dihydrospiro [ indene-2, 4' -piperidine) with reference to step (c-d) of example 5]-6-yl) ethan-1-one. MS:496 (M + H) + .
The following examples were synthesized with the corresponding starting materials in accordance with the above procedure.
TABLE 25
The following examples can be synthesized using the methods described above and suitable starting materials:
watch 26
Pharmacological testing
Example a phosphatase activity assay (single dose):
single dose inhibition assay, PTP was activated by co-incubation of SHP2 enzyme solution (diluted to 0.5nM in the reaction solution) with dPEG8 peptide in reaction solution (60mM 3, 3-dimethyl glutarate (pH 7.2), 75mM NaCl,75mM KCl,1mM EDTA,0.05% Tween 20,2mM Dithiothreitol (DTT)) for 30min using 6, 8-difluoro-4-methylumbelliferone phosphate (DiFMUP) as the reaction substrate. DMSO (0.5% (V/V) or compound (100 nM) was added to the mixture and incubation was continued at room temperature for 30min. DiFMUP (12. Mu.M, total volume of reaction solution 100. Mu.L) was added to start the reaction, after incubation for 30min the fluorescence intensity of the reaction solution (excitation light 340nM, emission light 450 nM) was measured using 2104-0020EnVision Xcite Multilabel Reader (Perkinelmer). Three wells were set for each dose. The fluorescence value of the control well (DMSO) was set to 100%, and the inhibitory activity of the compound-treated wells was expressed as a percentage of the control wells.
TABLE A
Phosphatase activity assay (IC 50 assay):
IC 50 value detection, PTP was activated by incubating 6, 8-difluoro-4-methylumbelliferone phosphate (DiFMUP) as a reaction substrate with SHP2 enzyme solution (diluted to 0.5nM in the reaction solution) and dPEG8 peptide in a reaction solution (60mM dimethyl 3, 3-glutarate (pH 7.2), 75mM NaCl,75mM KCl,1mM EDTA,0.05% Tween 20,2mM Dithiothreitol (DTT)) for 30 minutes. DMSO (0.5% (V/V) or a compound (concentration: 0.3 nM-1. Mu.M) was added to the mixture, incubation was continued at room temperature for 30min, diFMUP (12. Mu.M, total volume of reaction solution: 100. Mu.L) was added to start the reaction, and after incubation for 30min, the fluorescence intensity (excitation light 340nM, emission light 450 nM) of the reaction solution was measured with 2104-0020EnVision Xcite Multilabel Reader (Perkinelmer). The IC of the present invention, in which the compound inhibits the enzymatic activity of SHP2, was used 50 See table B.
Table B
Example C cell proliferation assay:
MV-4-11 cells (4000 cells/well) were plated in 96-well plates in a medium of 100. Mu.L/well (IMDM containing 3% Fetal Bovine Serum (FBS), from Gibco). After 24 hours of incubation, compounds of the invention formulated to different concentrations were added. On day 8, 30. Mu.L of MTS/PMS reagent (purchased from Promega, sigma, respectively) was added to each well, and absorbance was measured according to the protocol (Promega). IC of the Compounds of the invention 50 The values are shown in Table C.
Watch C
Example D p-ERK cellular level assay
The level of activation of ERK1/2 was detected by immunoblotting using an anti-p-ERK 1/2 antibody. Briefly, MV-4-11 human leukemia cells were incubated with a range of compounds (concentrations from 0.3nM to 100 nM) for 2 hours. Cells were lysed using RIPA buffer (Thermo Fisher Scientific, rockford, IL, USA) containing a cocktail of Halt protease inhibitors and total cellular protein was recovered. mu.L of total protein was separated by SDS-PAGE under reducing conditions and transferred to PVDF membrane (Bio-Rad). After blocking with Tris buffered saline solution containing 5% bsa, the membrane was incubated with primary antibody overnight at 4 ℃ followed by 1 hour incubation with horseradish peroxidase (HRP) labeled secondary antibody. The bound secondary antibody is detected using chemiluminescence.
Example E MV-4-11 xenograft tumor model
MV-4-11 cell culture was expanded, collected and injected subcutaneously into 5-8 week old female NOD/SCID mice (5X 10) 6 Individual cells per mouse, n = 6-10 per group). When the average tumor volume is about 100-200mm 3 At that time, oral gavage (0.1-10 mpk/dose) is initiated. During the treatment period (once or twice a day for 2-4 weeks), tumor volumes were measured using a vernier caliper. Differences in tumor volume between groups were counted using a one-way ANOVA analysis. The solvent is a negative control.
The compounds provided herein are preferably formulated into pharmaceutical compositions for administration by various routes. Most preferably, the pharmaceutical composition is for oral administration, such pharmaceutical compositions and methods for their preparation are well known in the art, see, e.g., remington: pharmaceutical SCIENCE AND PRACTICE (A. Gennaro, et al eds.,19 th edition, mic publishing company, 1995) [ REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds.,19 th ed.,Mack Publishing Co.,1995)]The compounds of formula I, II, III or IV are generally effective over a wide dosage range.
In summary, most of the compounds listed in this invention are very potent and selective with an IC50 of less than 10nM. They also show good antitumor effects in vivo models. For example, daily dosages typically fall within the range of about 0.2mg to 100mg dosages, preferably 0.2mg to 50mg dosages, more preferably 0.2mg to 20mg dosages. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed. The above dosage ranges do not limit the scope of the invention in any way. It will be understood that the actual amount of the compound administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's condition.
Claims (6)
1. Use of a compound or a pharmaceutical composition thereof, wherein the compound is 1'- (5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 7-dihydrospiro [ cyclopenta [ b ] pyridine-6, 4' -piperidin ] -5-amine or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or disorder mediated by the activity of SHP 2.
2. Use of a compound, or a pharmaceutical composition thereof, in the manufacture of a medicament for the treatment or prevention of a disease or disorder mediated by the activity of SHP2, wherein the compound is (S) -1'- (5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -5, 7-dihydrospiro [ cyclopenta [ b ] pyridine-6, 4' -piperidin ] -5-amine or a pharmaceutically acceptable salt thereof.
3. The use according to claim 1 or 2, the pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.
4. The use of claim 3, wherein the weight ratio of the compound or pharmaceutically acceptable salt thereof to the adjuvant is in the range of about 0.0001 to about 10.
5. The use of claim 1 or 2, the disease or disorder mediated by the activity of SHP2 is cancer, cancer metastasis, cardiovascular disease, immune disorders, fibrosis or visual disorders.
6. The use according to claim 1 or 2, wherein the disease or condition mediated by the activity of SHP2 is selected from noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myelogenous leukemia, breast cancer, esophageal tumor, lung cancer, colon cancer, head cancer, lymphoma, glioblastoma, gastric cancer, pancreatic cancer and combinations thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211420369.9A CN115969853A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810440520.2A CN110143949A (en) | 2018-05-09 | 2018-05-09 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
CN202211420369.9A CN115969853A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810440520.2A Division CN110143949A (en) | 2018-05-09 | 2018-05-09 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115969853A true CN115969853A (en) | 2023-04-18 |
Family
ID=67589146
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011087795.6A Active CN112409334B (en) | 2018-05-09 | 2018-05-09 | Heterocyclic derivatives useful as SHP2 inhibitors |
CN202211420369.9A Pending CN115969853A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN202211429954.5A Pending CN115721648A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN201810440520.2A Pending CN110143949A (en) | 2018-05-09 | 2018-05-09 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
CN202211429905.1A Pending CN116003321A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN202011087825.3A Active CN112174935B (en) | 2018-05-09 | 2018-05-09 | Heterocyclic derivatives useful as SHP2 inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011087795.6A Active CN112409334B (en) | 2018-05-09 | 2018-05-09 | Heterocyclic derivatives useful as SHP2 inhibitors |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211429954.5A Pending CN115721648A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN201810440520.2A Pending CN110143949A (en) | 2018-05-09 | 2018-05-09 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
CN202211429905.1A Pending CN116003321A (en) | 2018-05-09 | 2018-05-09 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN202011087825.3A Active CN112174935B (en) | 2018-05-09 | 2018-05-09 | Heterocyclic derivatives useful as SHP2 inhibitors |
Country Status (1)
Country | Link |
---|---|
CN (6) | CN112409334B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2018081091A1 (en) | 2016-10-24 | 2018-05-03 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
CN112166110B (en) | 2018-03-21 | 2023-08-11 | 传达治疗有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
CN112351780B (en) | 2018-05-02 | 2023-12-01 | 纳维尔制药有限公司 | Substituted heterocyclic inhibitors of PTPN11 |
CN112409334B (en) * | 2018-05-09 | 2022-12-02 | 北京加科思新药研发有限公司 | Heterocyclic derivatives useful as SHP2 inhibitors |
CR20210132A (en) | 2018-08-10 | 2021-07-20 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
US20210393623A1 (en) * | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
TW202028183A (en) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | Nitrogen-containing heteroaryl derivative regulators, preparation method and application thereof |
CN117143079A (en) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
WO2020156243A1 (en) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2 inhibitor and application thereof |
KR20220066923A (en) | 2019-09-24 | 2022-05-24 | 릴레이 테라퓨틱스, 인크. | SHP2 phosphatase inhibitors and methods of making and using the same |
CN112574212B (en) * | 2019-09-30 | 2022-04-19 | 上海拓界生物医药科技有限公司 | Pyrimido five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof |
CN113024508A (en) * | 2019-12-25 | 2021-06-25 | 天津医科大学 | Nitrogen heterocyclic ring derivative and preparation method and application thereof |
WO2021143680A1 (en) * | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | Heteroaryl derivative, preparation method therefor, and use thereof |
WO2021147879A1 (en) * | 2020-01-21 | 2021-07-29 | 贝达药业股份有限公司 | Shp2 inhibitor and application thereof |
TW202144334A (en) * | 2020-04-03 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | The crystal form of the free alkali of nitrogen-containing aromatic derivatives |
WO2021218752A1 (en) * | 2020-04-26 | 2021-11-04 | Betta Pharmaceuticals Co., Ltd | Shp2 inhibitors, compositions and uses thereof |
WO2021218755A1 (en) * | 2020-04-30 | 2021-11-04 | 贝达药业股份有限公司 | Shp2 inhibitor, and composition and use thereof |
US20230339882A1 (en) * | 2020-07-24 | 2023-10-26 | Betta Pharmaceuticals Co., Ltd. | Shp2 inhibitor and composition and application thereof |
WO2022063190A1 (en) * | 2020-09-23 | 2022-03-31 | 南京明德新药研发有限公司 | Pyrazine thiobiphenyl compound and application thereof |
TW202244049A (en) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技(上海)有限公司 | Preparation and Application of SHP2 Phosphatase Inhibitor |
CN115960109B (en) * | 2021-05-31 | 2024-06-25 | 药雅科技(上海)有限公司 | Preparation and application of condensed ring SHP2 phosphatase inhibitor |
JP2024519098A (en) * | 2021-05-21 | 2024-05-08 | 石薬集団中奇制薬技術(石家庄)有限公司 | Spiro compounds and uses thereof |
WO2023051606A1 (en) * | 2021-09-28 | 2023-04-06 | 上海翰森生物医药科技有限公司 | Medical use of shp2 inhibitor in combination with egfr-tki in treatment and prevention of tumor diseases |
WO2023072191A1 (en) * | 2021-10-27 | 2023-05-04 | 正大天晴药业集团股份有限公司 | Pyrrolopyrazole spiro compound |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
CN115611869A (en) * | 2022-05-11 | 2023-01-17 | 山东大学 | Heterocyclic pyrazine derivative and application thereof in preparation of SHP2 inhibitor |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024113194A1 (en) * | 2022-11-30 | 2024-06-06 | Canwell Biotech Limited | Shp2 inhibitors, compositions and methods thereof |
CN118206550A (en) * | 2022-12-15 | 2024-06-18 | 江苏威凯尔医药科技有限公司 | SHP2 inhibitor and application thereof |
CN118005535A (en) * | 2024-04-10 | 2024-05-10 | 天津市长芦化工新材料有限公司 | Synthesis method of perfluoro-isobutyronitrile |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102388052A (en) * | 2009-04-01 | 2012-03-21 | 诺瓦提斯公司 | Spiro derivatives for the modulation of stearoyl-CoA desaturase |
CN105916845A (en) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2017211303A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN107787226A (en) * | 2015-03-25 | 2018-03-09 | 诺华股份有限公司 | Drug regimen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
ES2805232T3 (en) * | 2015-06-19 | 2021-02-11 | Novartis Ag | Compounds and compositions to inhibit SHP2 activity |
CN112409334B (en) * | 2018-05-09 | 2022-12-02 | 北京加科思新药研发有限公司 | Heterocyclic derivatives useful as SHP2 inhibitors |
-
2018
- 2018-05-09 CN CN202011087795.6A patent/CN112409334B/en active Active
- 2018-05-09 CN CN202211420369.9A patent/CN115969853A/en active Pending
- 2018-05-09 CN CN202211429954.5A patent/CN115721648A/en active Pending
- 2018-05-09 CN CN201810440520.2A patent/CN110143949A/en active Pending
- 2018-05-09 CN CN202211429905.1A patent/CN116003321A/en active Pending
- 2018-05-09 CN CN202011087825.3A patent/CN112174935B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102388052A (en) * | 2009-04-01 | 2012-03-21 | 诺瓦提斯公司 | Spiro derivatives for the modulation of stearoyl-CoA desaturase |
CN105916845A (en) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
CN107787226A (en) * | 2015-03-25 | 2018-03-09 | 诺华股份有限公司 | Drug regimen |
WO2017211303A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CN112409334A (en) | 2021-02-26 |
CN115721648A (en) | 2023-03-03 |
CN116003321A (en) | 2023-04-25 |
CN112174935B (en) | 2022-12-06 |
CN110143949A (en) | 2019-08-20 |
CN112174935A (en) | 2021-01-05 |
CN112409334B (en) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112409334B (en) | Heterocyclic derivatives useful as SHP2 inhibitors | |
TWI664175B (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
CN112250670B (en) | Novel heterocyclic derivatives useful as SHP2 inhibitors | |
CN107011348B (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | |
CA3161278A1 (en) | Sos1 inhibitors | |
TWI697490B (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
TW202014416A (en) | Pyridazinones as parp7 inhibitors | |
CN115515946A (en) | SHP2 inhibitor and composition and application thereof | |
JP2008521873A (en) | Pyrrolopyridine-2-carboxylic acid amides | |
WO2023169170A1 (en) | Heterocyclic compound as shp2 inhibitor, composition comprising heterocyclic compound, and method using same | |
WO2024026479A2 (en) | Cdk2 inhibitors and methods of using the same | |
WO2024026483A2 (en) | Cdk2 inhibitors and methods of using the same | |
CN118055934A (en) | PARG inhibitory compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |